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ABSTRACT 
 Prostate cancer (PCa) is the second leading cause of cancer and cancer-related deaths in 
U.S. men. Dietary strategies to prevent or reduce PCa would have a significant impact on public 
health. The American Institute for Cancer Research (AICR) recommends consuming a variety of 
fruits, vegetables, whole grains, and legumes for cancer prevention. Specifically, 
epidemiological studies suggest that consumption of tomato or soy products may reduce the risk 
of PCa.  
 Tomatoes contain many bioactive components, but the tomato carotenoids, lycopene, β-
carotene, phytoene, and phytofluene, receive much of the attention regarding PCa incidence. As 
tomato carotenoids are lipophilic, strategies to enhance absorption and tissue distribution have 
been of interest. Evidence suggests that co-consumption of tomato carotenoids with a source of 
dietary fat increases their absorption and bioavailability, however, the influence of fat type on 
tomato carotenoid tissue accumulation has not been well understood. Therefore, we fed 
Mongolian gerbils (Meriones unguiculatus) a 20% fat diet containing 10% tomato powder (TP) 
and either safflower oil (polyunsaturated fat) or coconut oil (saturated fat) and determined the 
influence of dietary fat type on tissue carotenoid bioaccumulation.  
Coconut oil fed-gerbils had increased tissue carotenoid concentrations including total 
carotenoids in the serum (p=0.0003), adrenal glandular phytoene (p=0.04), hepatic phytofluene 
(p=0.0001), testicular all-trans lycopene (p=0.01), and cis-lycopene (p=0.006) in the prostate-
seminal vesicle complex compared to safflower oil. Safflower oil-fed gerbils had greater splenic 
lycopene concentrations (p=0.006) compared to coconut oil-fed gerbils. Additionally, coconut oil 
feeding increased serum cholesterol (p=0.0001), and decreased hepatic cholesterol (p=0.0003) 
compared to safflower oil. Coconut oil enhanced tissue uptake of tomato carotenoids to a greater 
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degree than safflower oil, and these results may have been due to the large proportion of medium 
chain fatty acids in coconut oil which might have caused a shift in cholesterol flux to favor 
extrahepatic carotenoid tissue deposition.  
 In vivo studies examining the effect of TP or tomato paste on PCa have demonstrated 
mostly positive results. However, these studies often model lifelong consumption of tomato 
products (initiated post-weaning, ~4 weeks of age) and may not accurately reflect the changes in 
dietary patterns or supplement use in men newly diagnosed with PCa. Therefore, we designed a 
10% TP diet intervention in TRAMP mice to determine the effects of consuming TP (post-
puberty, ~5-6 weeks of age) during the process of carcinogenesis on PCa incidence.  
8-week-old male C57BL/6 X FVB TRAMP mice were randomized to consume either an 
AIN-93G + 10% TP diet (N=90) or the AIN-93G control diet (N=88) and assigned to one of 
three sacrifice ages: 12 (N=59), 16 (N=60), or 20 (N=59) weeks. Overall cancer incidence was 
not impacted by diet at any time point. However, at 16 weeks of age, TP significantly increased 
high-grade PIN (HGP) (p=0.014) and significantly decreased poorly-differentiated (PD) 
(p=0.024) lesions compared to the control diet suggesting a modest reduction in cancer 
progression by TP at 16 weeks of age.  
There are two variables that may explain the modest effect of TP in this study: the low 
amount of lycopene in the TP diet and the timing of the dietary intervention. The TP diet 
contained 30-fold less lycopene than a previous study in our lab.  However, after 8 and 12 weeks 
of feeding, mice accumulated similar tissue concentrations of carotenoids in their serum, gonadal 
adipose, and prostate suggesting that the amount of carotenoids in the diet may not have been the 
critical factor since tissue levels of lycopene appear to become saturated with long-term feeding. 
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Rather, the initiation of the diet intervention at 8 weeks of age instead of 4 weeks of age may 
have been too late in cancer development to substantially impact carcinogenesis, as studies have 
shown prostate-specific gene expression changes as early as 8-10 weeks of age in TRAMP mice. 
We histopathologically confirmed that mice had low-grade and moderate-grade PIN at 8 weeks 
of age, when the dietary intervention was initiated. The TRAMP model is an aggressive model of 
PCa, therefore, diet may not be able to have as great of an impact when initiated after puberty 
(~6 weeks of age) when PCa is developing rapidly in this model. Both the late intervention time 
combined with low levels of carotenoids in the TP diet may have contributed to the lack of an 
overall effect. This study re-emphasizes the importance of lifelong consumption of TP for PCa 
prevention.   
Epidemiological studies have also associated soy consumption with a decreased risk of 
PCa. One hypothesis for the decreased risk of PCa by soy consumption is the production of the 
microbial-metabolite, equol, from daidzein. A TRAMP study from our lab suggested that a 2% 
soy germ diet reduced PCa incidence by 34%. The same study observed that prostatic equol 
concentrations were 39 times greater than prostatic genistein and 3 times higher than prostatic 
daidzein suggesting that equol may have been a significant factor in reducing PCa incidence. We 
aimed to determine if equol was responsible for the protective effect of soy germ by replicating 
that study with additional dietary groups.  
3-week old male C57BL/6 X FVB TRAMP mice were weaned from our breeding colony 
and immediately acclimated to an AIN-93G control diet for one week. At 4 weeks of age, mice 
(n=30 per diet group) were randomized to one of four pelleted study diets, AIN-93G control, 
AIN-93G + 2% soy germ, AIN-93G + 92 ppm daidzein, or AIN-93G + 88 ppm equol until 18 
weeks of age. To our surprise, we did not detect any statistical differences in cancer incidence 
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between diets. In the previous study, we observed a 100% cancer incidence in TRAMP mice fed 
a control diet until 18 weeks of age, however, the control group in this study only had a 24% 
incidence in cancer at 18 weeks of age. Additionally, mice in the current study had less food 
intake and significantly decreased body weights (p<0.001) compared to those in the previous 
study. A reduction in food intake and body weight is known to reduce cancer incidence in a 
number of animal models and is likely to have contributed to the decrease in expected cancer 
incidence in the current study. We hypothesize that the reason for the decreased food intake, the 
decreased body weight, and decreased cancer incidence was due to the physical format of the 
study diets. Mice in the current study were fed pelleted diets, whereas mice in the previous study 
were fed powdered diets. Differences between powdered and pelleted diets exist and have been 
shown to influence obesity which, in turn, can affect cancer development.  
Additionally, we measured serum levels of cytokines in mice with tumors and in mice 
with high-grade PIN. In mice with tumors, daidzein and equol diets significantly altered the 
levels of IL-1β, IL-10, IFN-γ, and TNF-α compared to the control and soy germ groups 
suggesting that daidzein and equol may play a role in moderating systemic inflammation in 
advanced PCa. While our diets did not impact overall cancer incidence in this study, the role of 
daidzein and equol in PCa still warrants investigation.  
 Overall our findings suggest that consuming fruits and vegetables containing bioactives 
such as carotenoids or isoflavones may be beneficial in reducing PCa incidence. The co-
consumption of fat with carotenoids can increase their bioavailability and tissue biodistribution. 
Lifelong consumption of carotenoid-containing fruits and vegetables is likely more protective 
than changes to the diet or supplement use at the time of cancer diagnosis. Lastly, the format of 
the diet is important to consider when studying the effects of bioactives in cancer models. 
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Nonetheless, dietary strategies to reduce the risk of PCa remain of interest and of public health 
significance. 
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CHAPTER 1 
Literature Review 
INTRODUCTION 
Cancer development is a complex and multi-step process. In 2000, Hanahan and 
Weinberg outlined six essential alterations in cellular physiology which determine malignant 
growth
1
. Sustained proliferative signaling, evasion of growth suppressors, active invasion and 
metastases, acquired unlimited replicative potential, induced angiogenesis, and evasion of cell 
death were termed the Hallmarks of Cancer
1
. These six hallmarks were expanded in 2011 to 
include emerging hallmarks and enabling characteristics such as the avoidance of immune 
system destruction, tumor-promoting inflammation, genomic instability, and deregulated cellular 
energetics in an effort to further describe strategies cancer cells possess and develop to survive. 
Once thought to be primarily influenced by hereditary factors alone, research now suggests only 
5-10% of cancer cases can be attributed solely to hereditary causes
2,3
. The remaining 90-95% of 
cancer cases are thought to be primarily influenced by environmental factors including 
epigenetics and dietary habits
2
. The 2007 AICR/WCRF Report suggests that “cancer is 30-40% 
preventable over time by appropriate food and nutrition, regular physical activity, and avoidance 
of obesity”4. Though significant, the risk for cancer development depends on a multitude of 
factors including the entire diet profile, type of cancer, other environmental factors, and genetics 
of the individual. Despite evidence that suggests that the association between intakes of total 
fruits and vegetables and cancer incidences is weak, specific types of fruits and vegetables have 
been inversely associated with cancer incidences, including soy and tomatoes
5,6
.  
Prostate cancer (PCa) is the most common cancer in men and is the second leading cause 
of cancer deaths in men in the US with an estimated 233,000 new cases diagnosed in 2014
7
. Risk 
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factors for PCa include age, genetics, family history, race, smoking, obesity, and diet
8
. The 
pathological progression of PCa is classified as follows: normal prostate epithelium, prostatic 
epithelial neoplasia (PIN), localized PCa, metastatic PCa, and castration-resistant PCa (CRPC)
9
. 
Due to increased screening and earlier detection of PCa, recommendations for localized prostate 
cancers often include “watchful waiting” or “active surveillance” which involves frequent 
monitoring of the disease by digital rectal examinations and prostate-specific antigen (PSA) 
levels in an attempt to avoid costly and unnecessary treatments with negative side effects. The 
slow-progressing nature of PCa combined with early detection provides an ideal window of time 
where dietary interventions may be beneficial. Men diagnosed with PCa often turn to dietary 
supplements as an inexpensive way to reduce the risk of cancer progression
10
. The use of 
supplements marketed towards men for prostate health has been estimated at 13% in men with 
PCa, but may actually be higher due to the unreported use of complementary and alternative 
medicine (CAM)
10
. In the 2007 report, the American Institute for Cancer Research and World 
Cancer Research Fund (AICR/WCRF) emphasized a diet rich in plant foods to reduce cancer 
risk
4
. There is a need to investigate the anticarcinogenic properties of bioactive compounds from 
fruits and vegetables for PCa protection. 
Tomato for Prevention of Prostate Cancer 
Tomato consumption has been linked to decreased risk of chronic diseases
11
. In addition 
to vitamins A, C, and E, tomatoes are excellent sources of potassium, fiber, and folate
12
. 
Furthermore, tomatoes contain a variety of flavonols such as quercetin and kaempferol and 
carotenoids such as lycopene, phytoene, phytofluene, α-carotene, ζ-carotene, and β-carotene12. 
Individually, many components in tomatoes have been investigated for their anti-cancer and 
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antioxidant properties, but the combination of these components may best contribute to the 
numerous health benefits of tomatoes.  
Tomatoes and Prostate Cancer – Epidemiologic Evidence 
In 1995, Giovannucci et al. reported that the intake of lycopene-rich foods including 
tomatoes, tomato sauce, and pizza was associated with a significant risk reduction for total PCa 
(RR=0.65) and advanced PCa (RR=0.47)
13,14
. Recently, further analyses of data from the Health 
Professionals Follow-Up Study demonstrated a significant inverse association between lycopene 
intake and the incidence of lethal PCa (HR=0.72)
13
. These studies also suggest that early and/or 
lifelong lycopene intake is more important for PCa risk reduction than recent lycopene intake. A 
2004 meta-analysis of 11 case-control studies and 10 cohort studies indicated a relative risk of 
0.89 in men consuming high intakes of tomato products and PCa incidence, and a further 
reduction in relative risk (RR=0.81) in men consuming high intakes of cooked tomato products
15
. 
The results of this meta-analysis suggest that processing tomatoes enhances their protective 
effect against PCa. In contrast, the results of the Prostate Cancer Prevention Trial and Prostate, 
Lung, Colorectal, and Ovarian Cancer Screening Trial did not observe a significant association 
between tomato products or lycopene, and PCa risk
16,17
. The mixed results from the 
epidemiology were addressed in the 2014 Continuous Update Report for PCa from 
AICR/WCRF
8. In this updated report, evidence for lycopene’s effect on PCa was down-graded 
from “probable” to “limited-no conclusion” based on the analyses of recent human studies8. 
While the classification of lycopene has changed, the report recognized that the nuances between 
different prostate cancers, study designs, and populations, complicates the interpretation of the 
evidence for broad classifications of food and PCa risk
8
.  
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Tomatoes and Prostate Cancer - In vitro Evidence 
The mechanism by which tomatoes and tomato products may reduce PCa risk has not 
been elucidated. The major carotenoid found in tomatoes, lycopene, is responsible for their red 
color and has been suggested as the primary bioactive constituent. Lycopene has been reported to 
protect against oxidation, induce cell-cycle arrest, inhibit proliferation, increase apoptosis, inhibit 
angiogenesis, and disrupt growth factor and hormonal signaling in vitro
18–21
. One study 
demonstrated that lycopene combined with a common carbohydrate derivative found in dried 
tomato products, ketosamine, reduced growth in MAT-LyLu cells
22
. That study suggested that 
other components in tomatoes may also be protective against PCa.  
Tomatoes and Prostate Cancer – Pre-clinical Animal Trials 
There are a handful of studies examining the effect of tomato powder (TP) on PCa in vivo 
(Tab1e 1.1)
20,23–25
. In N-methyl-N-nitrosourea (NMU) testosterone-treated rats, a 10% TP diet 
increased overall PCa-free survival compared to the control diet and the lycopene supplemented 
diet
23
. The findings from this study suggested that components in TP, in addition to lycopene, 
were protective against PCa development. In the Dunning R3327-H model of PCa, a 10% TP 
diet significantly decreased tumor weights, increased apoptosis, and decreased proliferation 
compared to the control diet
20
.  Furthermore, lycopene alone did not significantly reduce 
tumorgenesis, further supporting the hypothesis that tomatoes contain other bioactive compounds 
necessary for PCa prevention. In the transgenic adenocarcinoma of the mouse prostate (TRAMP) 
PCa model, a 10% TP diet increased survival and decreased PCa incidence compared to the 
control diet
24,26
. Interestingly, it appears that TP may be more effective than tomato paste in 
animal studies of PCa. When PCa incidence was compared in the TRAMP model between diets 
matched for lycopene from tomato paste or supplemented from a commercial lycopene beadlet 
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source, only the lycopene beadlet diet significantly reduced PCa incidence compared to the 
control
27
. TP is manufactured with the tomato seeds and skins included, whereas tomato paste is 
processed without the seeds and skin
27
. It may be that compounds found in tomato seeds and/or 
skin may be protective against PCa. Overall, the vast majority of pre-clinical animal trials 
support the evidence from epidemiology that whole tomato products are more effective than 
lycopene alone at reducing the risk for PCa.  
Table 1.1. Summary of Rodent Studies of 10% Tomato Powder and Tomato Paste Diets and PCa 
Risk 
Author 
Animal 
Model 
Dietary 
Source of 
Lycopene 
Lycopene 
Exposure 
Study 
Outcome 
Effective? 
Zuniga et 
al. 2013
24
 
TRAMP mice 
10% Tomato 
Powder 
286 ppm PCa Incidence Yes 
Pannelini 
et al. 
2010
28
 
TRAMP mice 
10% Tomato 
Powder 
132 ppm Survival Yes 
Konijeti et 
al. 2010
27
 
TRAMP mice 
Tomato 
Paste 
28 ppm PCa Incidence No 
Wan et al. 
2014
29
 
TRAMP mice 
10% Tomato 
Powder 
384 ppm 
Androgen 
Metabolism 
and Signaling 
Yes 
Boileau et 
al. 2003
23
 
(NMU)-
Testosterone-
treated rats 
10% Tomato 
Powder 
13 ppm PCa Risk Yes 
Mossine et 
al. 2008
22
 
(NMU)-
Testosterone-
treated rats 
10% Tomato 
Powder 
unknown Survival Yes 
Canene-
Adams et 
al. 2007
20
 
Dunning 
R3327-H rats 
10% Tomato 
Powder 
7 ppm 
Prostate Tumor 
Weight 
Yes 
  
Tomatoes and Prostate Cancer – Clinical Trials 
 Several clinical trials have investigated the effect of lycopene supplementation and 
tomato product consumption in men with PCa. Intervention studies have shown that 
consumption of tomatoes or tomato products may protect against DNA strand breaks induced by 
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reactive oxygen species (ROS)
30
. Only a handful of randomized controlled clinical trials have 
tested lycopene’s efficacy in humans with PCa. Kucuk et al. determined that patients consuming 
15 mg of lycopene a day for 3 weeks prior to prostatectomy had decreased serum PSA levels and 
increased microscopically free resection margins compared to the control
31
. A 2 year 
intervention of 2 mg of lycopene twice a day significantly reduced serum PSA and significantly 
increased survival rate in men with metastatic PCa compared to the control
32
. In contrast, 15 mg 
of lycopene twice a day for 6 months did not reduced serum PSA compared to the control 
group
33
. And an 8 week intervention of lycopene and soy protein resulted in no changes in serum 
PSA between the groups
34
. Although human clinical trials have not yet demonstrated the 
chemopreventative effects of lycopene that pre-clinical rodent studies and epidemiological 
studies have shown, there is a need for additional well-designed and controlled intervention 
studies in men with PCa.  
3-Dimensional (3D) Ultrasound Imaging and Prostate Cancer 
Currently, 3-D ultrasound imaging is routinely used to guide systematic biopsy for PCa 
diagnosis and to monitor treatment response. The development of high-resolution ultrasound 
imaging for small laboratory animals provides a novel method to monitor tumor characteristics 
and changes in preclinical models. 3-D imaging has been able to detect tumor burden in two 
transgenic PCa models
35
. The use of 3-D longitudinal imaging to monitor dietary intervention 
provides a non-invasive means to quantify tumor burden and metastasis in vivo.  
Soy and Prostate Cancer 
Epidemiological studies suggest a reduced risk of PCa in men who consume soy 
products
36
. Soy products contain an array of bioactive compounds including saponins, lignans, 
and isoflavones, yet much of the research in cancer prevention has focused on the predominant 
7 
 
isoflavone found in soy foods, genistein. Genistein has been investigated for its anti-
proliferative, antioxidant, and chemopreventive properties in cell, animal, and human models of 
PCa
37
. 
Soy and Prostate Cancer – Epidemiologic Evidence 
 A disparity exists between PCa incidences around the world. The PCa incidence in Japan 
is one-fifth of that in the United States
38
. Migration studies have shown that PCa risk increases in 
men migrating from areas of low incidence to areas with high incidence
38
. Lifestyle, 
environmental, and dietary factors have been widely hypothesized to contribute to this variation. 
In addition to low intakes of saturated fat and higher intakes of dietary fiber, Asian populations 
also consume more soy products
39
. Mean serum isoflavone concentrations are higher in men 
from Japan than men from the United Kingdom and Finland suggesting that soy consumption 
may be responsible for differential PCa risk in these populations
38
. In the Japan Public Health 
Center (JPHC) – based Prospective Cohort Study, consumption of soy products, genistein, and 
daidzein were associated with a decreased risk of localized PCa
38
. A 2009 meta-analysis of 6 
cohort and 8 case-control studies, described a decreased risk of PCa (RR/OR of 0.74) with total 
soy consumption
40
. The RR/OR for Asian populations was 0.52 and for studies in Western 
populations was 0.99
40
. The dietary differences between populations with differing incidences of 
PCa may provide insight into mechanisms by which soy may reduce PCa risk.   
Soy and Prostate Cancer – In vitro Evidence 
The mechanism by which genistein and soy isoflavones protect against PCa has been 
extensively investigated in vitro. Soy isoflavones have structural similarity to 17β-estradiol and 
have weak estrogenic activity
41. It’s hypothesized that phytoestrogens, such as isoflavones, work 
primarily through estrogen receptor β (ERβ), though the exact mechanism is unknown. ERβ, 
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which has been shown to be anti-proliferative, has been proposed to be an important driver of 
prostatic epithelial differentiation
42. The use of ERβ-agonists in mice with prostatic hyperplasia 
resulted in a reduction of cellular proliferation and an increase in apoptosis in the prostate, and 
ERβ is suggested to be a promising target for PCa treatment42,43. Androgen receptor (AR) is a 
well-known regulator of benign and malignant prostatic proliferation and differentiation and is a 
the common target of current PCa therapeutic treatment
42
, however, the use of anti-androgens to 
bind AR can lead to a PCa that is incurable. In vitro studies have shown isoflavones induce cell-
cycle arrest, reduce cancer cell proliferation, and modulate cell-cycle signaling
41
. While genistein 
has been associated with a protective effect against several cancers and diseases, further research 
is needed to elucidate the effects of the other soy isoflavones and their metabolites, including 
glycitein, daidzein, dihydrodaidzein, and equol, and their impact on human health and disease 
prevention.  
Soy and Prostate Cancer – Pre-clinical Animal Trials 
Isoflavones, most notably genistein, have long been investigated for their effects in 
animal models of PCa. In Sprague-Dawley rats, 250-1000 ppm dietary genistein per day reduced 
AR and ER expression in the prostate
44,45
. Dietary genistein also reduced the incidence of poorly 
differentiated (PD) lesions in TRAMP mice in a dose-dependent manner
37
. In addition to 
genistein, studies using mixtures of isoflavones or isoflavones from soy products have also been 
effective at reducing PCa. Lobund-Wistar rats fed an isoflavone-rich diet had a significant 
reduction in tumor growth compared to control rats
46
. Soy germ is a commercially available 
supplement containing 50% of isoflavones from daidzein, 39% from glycitein, and 11% from 
genistein. It was recently demonstrated by our laboratory to decrease the incidence of PD PCa in 
the TRAMP model by 34% compared to the control
24
. Lastly, a diet containing soy protein 
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reduced tumor weight and volume in nude mice transplanted with LNCaP cells compared to the 
control diet
47
. Despite the growing body of evidence that soy products are protective against 
PCa, the mechanisms of protection by a combination of isoflavones and/or metabolites are 
relatively unknown.  
Soy and Prostate Cancer - Clinical Trials 
 Clinical trials using soy products have yielded mixed results concerning PCa prevention. 
In a clinical trial of 38 PCa patients, consumption of 160 mg/day of isoflavones from red clover 
resulted in a significant increase in apoptosis in prostate tumors
48
. Furthermore, in men with 
PCa, consumption of soy or isoflavones significantly decreased serum PSA compared to the 
controls
49–51
. This effect, however, was not observed among all studies in this population
48,52
. 
Lastly, the results of a phase II clinical trial in men with PCa given isoflavone supplements 
containing 52 mg of total isoflavone aglycone equivalents observed no change in PSA
53
. The 
conflicting results concerning PCa may be attributed to dose administered, sources of 
isoflavones, bioavailability of isoflavones, or specific type of soy intervention. Furthermore, 
differences between individuals including cancer stage and their ability to produce equol may 
further confound results.  
Equol and Prostate Cancer 
Epidemiological studies suggest an association between isoflavone intake and a 
decreased risk of PCa, especially in men who produce equol
36
. Equol is produced by the 
microbial metabolism of daidzein in the large intestine. It’s estimated that only 25-30% of the 
populations in Western countries are equol “producers” compared to up to 80% of individuals in 
China, Japan, and South Korea
54,55. An individual’s ability to produce equol is not fully 
understood, but it is thought that the gut microbiome, host genetics, and diet appear to contribute 
10 
 
to equol production from daidzein
56
. If the benefits from soy consumption are dependent upon 
equol production, an estimated 70-75% of the Western population would not benefit from soy 
consumption. Therefore, research is needed to determine whether cancer protection by soy 
consumption is dependent on equol production. Habitual intake of soy products early in life may 
be required to become an equol producer, as consumption of isoflavones in adulthood does not 
always convert a non-producer of equol into a producer
55
. Previously we observed that prostatic 
equol was 39 times higher than genistein and 3 times higher than daidzein in mice consuming 
soy germ
24
. The elevated concentration of equol in the prostate suggests that equol was a 
potential major contributor to the anticarcinogenic effects of soy germ observed in the TRAMP 
model
24
. 
Equol has been demonstrated to be more estrogenic than daidzein
54
 and has a higher 
binding affinity for ERβ. Equol has been shown to bind ERα and ERβ with similar affinity as 
genistein
57
. Equol has also been shown to bind 5-α-dihydroxytestosterone (DHT) in vivo thereby 
reducing prostate growth by sequestering DHT from the AR
58
. By sequestering DHT from the 
AR, equol functions similar to anti-androgen drugs without interfering with DHT synthesis or 
AR signaling, which can have additional biological consequences. Equol was also shown to 
inhibit PCa cell growth and invasion by down-regulating matrix metalloproteinases in vitro
59,60
.  
Equol’s ability to be a selective estrogen modulator as well as an androgen antagonist makes it a 
promising target to study for hormonally-driven cancers like PCa. Limited in vivo studies have 
directly examined feeding equol and the incidence of PCa in rodents. Due to the previously 
observed protective effect of soy germ from our lab
24
, additional research is needed to elucidate 
if the protective effect of soy germ is attributed to equol production and if so, if the protective 
effect of soy germ limited to equol producers. 
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Tomato Carotenoid Bioavailability and Absorption 
The structure of carotenoids is based on a C40 isoprenoid backbone that may be cyclic or 
acyclic and have polar groups. Carotenoids containing at least one oxygen atom are classified as 
xanthophylls, while carotenes are characterized by a hydrocarbon structure. While over 600 
carotenoids have been identified in nature, only 60 or so appear to be consumed in the diet. 
Interest in the structure and function of carotenoids stems from epidemiological evidence 
supporting the protective effects of carotenoid-rich fruits and vegetables against many chronic 
and degenerative diseases including cardiovascular disease, age-related macular degeneration, 
and some cancers
14,61,62
.  
Bioavailability describes the degree to which ingested compounds like carotenoids may 
be absorbed and utilized from various food sources
63
. Once released from the food matrix, 
carotenoids are incorporated into mixed micelles with bile salts where they are then believed to 
be transported into intestinal cells through the B type-1 (SRB-1) receptor as well as the cluster 
determinant 36 (CD36)
64,65
. Once inside intestinal cells, carotenoids are packed into 
chylomicrons and secreted into the lymphatic system
64
. In the plasma, carotenoids are 
transported via lipoproteins and distributed to different tissues. There are several factors that 
influence carotenoid absorption and bioavailability including carotenoid species, the food matrix, 
processing factors, host genetics, nutrient interactions, and the co-consumption of dietary fat
63,66
. 
The presence of dietary fat with a carotenoid-containing meal has been shown to increase 
carotenoid absorption and bioavailability in humans
67–69
. Interestingly, the type of dietary fat has 
also been shown to impact carotenoid bioavailability. In humans, beef tallow (rich in saturated 
fat) increased post-prandial β-carotene content in chylomicrons compared to sunflower oil 
(polyunsaturated-rich fat)
70
. However, butter reduced the post-prandial chylomicron response 
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when compared to monounsaturated olive oil and polyunsaturated sunflower oil
71
. In addition to 
degree of saturation, fatty acid chain length also appears to be an important aspect of carotenoid 
absorption and bioavailability. Medium chain triglycerides appear to be better at solubilizing 
carotenes, whereas long-chain triglycerides may facilitate micellarization and incorporation into 
chylomicrons
70,72–74
. Differing structural properties and degrees of saturation appear to play a 
key role in carotenoid absorption and metabolism.  
Upon distribution to tissues, carotenoids such as β-carotene, α-carotene, and β-
cryptoxanthin are cleaved symmetrically at their central double bond by β-carotene 15, 15’-
oxygenase (BCO1)
65. β-carotene can be cleaved into two molecules of retinal which can be 
further reduced to retinol or oxidized to retinoic acid. BCO1 has been shown to have little or no 
activity cleaving non-provitamin A carotenoids in vivo
65. The existence of β-carotene-9, 10’-
oxygenase (BCO2) has been detected in mice, humans, and zebra fish and shares an overall 
sequence homology with BCO1
65
. BCO2 has a stronger affinity for cleavage of non-provitamin 
A carotenoids, such as lycopene, lutein, and zeaxanthin
65,75
. BCO2 cleaves eccentrically 
resulting in apo-carotenals
65
. The biological effects of apo-lycopenals are largely unknown, but 
apo-lycopenals have been shown to be metabolically active and may play important roles in the 
protective effect of tomatoes
65
.  
Soy Isoflavone Absorption and Bioavailability  
 Isoflavones are present in soy-containing foods as β-glycosides, aglycones, malonyl-
glycosides, and acetyl-glycosides
76. Upon digestion of soy products, β-glucosidases located on 
the brush border membrane of the intestine or from bacteria, cleave genistin, daidzin, and 
glycitin into a sugar and respective aglycone. The resulting aglycones, genistein, daidzein, and 
glycitein, are then absorbed by passive diffusion into the enterocytes, glycosylated, 
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glucoronidated, or sulphated by intracellular enzymes, and exit the enterocyte by facilitated 
transport into portal circulation
77
. Aglycones that enter portal circulation can be conjugated in the 
liver, kidney, and other organs
77
. Not all aglycones are absorbed by enterocytes. The ones that 
make it to the large intestine are metabolized by microbes. Genistein can be metabolized into 
dihydrogenistein and further reduced to p-ethyl phenol or 6’ –hydroxy-o-desmethylangolensin78. 
Little is known about the metabolites of glycitein. Demethylated glycitein metabolites have been 
detected in vitro and in vivo
78–80
. Daidzein can be reduced into dihydrodaidzein and further 
metabolized into (S)-equol and O-desmethylangolensin (O-DMA)
78
.  
Safety and Efficacy of Soy Germ 
 The vast majority of research on PCa and soy is focused on studies examining intake of 
soy foods (fermented and non-fermented) and isoflavone supplements. However, there are 
commercially-available alternative soy products that contain isoflavones that are marketed 
towards consumers for health benefits. Soy germ, the hypocotyl of the soy bean, is a 
commercially-available product derived from soy beans that is currently being investigated for 
its effects in inflammatory bowel disease (IBD), diabetes, and PCa
24,81–83
. Soy germ is unique in 
that it is not chemically processed, but has a high concentration of isoflavones
84
. The radically 
different isoflavone profile has been suggested to confer health benefits in humans. Soy germ 
contains a greater proportion of the isoflavone, daidzein, followed by glycitein, and then 
genistein. The larger proportion of daidzein may be significant because of the microbial 
conversion of daidzein into equol and the potential health benefits associated with equol. Soy 
germ-enriched pasta was shown to reduce serum LDL cholesterol, decrease arterial stiffness, 
reduce blood pressure, and reduce markers of oxidative stress in humans
81,82
. Furthermore, the 
effects were more pronounced in individuals who were capable of producing equol, further 
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suggesting that equol production may be the key to the efficacy of soy germ
81
. The incorporation 
of soy germ into a beverage for human consumption resulted in no toxicity, excellent 
compliance, and good absorption and bioavailability of isoflavones making it a suitable vehicle 
for future cancer prevention trials
85
.  In TRAMP mice fed a modified diet containing 2% soy 
germ, a 34% reduction in PCa incidence was observed
24
. The results of these studies suggest that 
soy germ may be successfully incorporated into a variety of foods for disease prevention studies.  
The TRAMP model 
The TRAMP model is a transgenic model of PCa. The rat probasin promoter’s response 
to androgens at puberty causes the prostate-specific expression of the Simian virus 40 large T 
antigen which suppresses tumor suppressors, p53 and Retinoblastoma (Rb)
86
. The suppression of 
these genes results in uncontrolled prostatic proliferation and eventual carcinoma. The TRAMP 
model develops multi-stage prostate carcinogenesis that exhibits similar pathological and 
molecular features to human PCa
86
 starting with prostatic intraepithelial neoplasia (PIN) to well-
differentiated carcinoma and eventually a poorly differentiated carcinoma with metastases 
primarily to the periaortic lymph nodes, liver, and lungs (Figure 1.1). Figure 1.2 shows 
examples of the range of histological grades of TRAMP mouse prostate tissue at 18 weeks of 
age
24
. The TRAMP model has been extensively utilized to examine dietary bioactives’ 
anticarcinogenic properties
24,28,37
.   
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Figure 1.1. Prostate Cancer Progression in the TRAMP Model
87
 
 
Figure 1.2. TRAMP Mouse Prostate Pathology Grades at 18 Weeks of Age 
 
Low-grade PIN (A), moderate-grade PIN (B), high-grade PIN (C), well-differentiated carcinoma 
(D), moderately-differentiated carcinoma (E), poorly-differentiated carcinoma (F). Images were 
captured from Nanozoomer-scanned slides with NDP view software at 40X digital zoom
24
.  
Angiogenesis, EMT, and Prostate Cancer 
The initial stages of tumor invasion require angiogenesis, the formation of new blood 
vessels to support tumor growth. Vascular endothelial growth factor (VEGF) signals though 
VEGF receptors to recruit endothelial cells for the formation of new capillaries. VEGF has been 
shown to be over expressed in PCa, and diets rich in tomato products have been shown to reduce 
VEGF levels in men with recurring PCa
28,88
. Data from the Health Professionals’ Follow-Up 
Study demonstrated that men with higher lycopene intakes had tumors that displayed less 
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angiogenic potential
13
. Furthermore, the inhibition of migration and invasion by lycopene was 
accompanied by reduced activity of matrix metalloproteinase 2 (MMP-2) and urokinase-type 
plasminogen activator (uPA) which are involved in extracellular matrix degredation
89
. This 
evidence suggests that lycopene may reduce the aggressive potential of PCa by inhibiting 
angiogenesis. Following angiogenesis, cancer cells can migrate to new tissues and form 
metastases. This process is known as the epithelial to mesenchymal transition (EMT) and is a 
critical process for invasion and metastasis of cancer cells. EMT requires the epithelial cells to 
change their morphology and gene expression, assuming the shape and characteristics of 
mesenchymal cells. The loss of cytokeratin, E-cadherin, and cellular polarity coupled with the 
acquisition of a fibroblast-like shape, motility, N-cadherin, proteases, and vimentin are 
characteristics of cells undergoing EMT. In vivo evidence demonstrates that tomato 
supplementation may reduce PCa metastases
28
, but the ability of TP to reduce the initial invasive 
potential by inhibiting the EMT switch is under investigated. 
Caloric Restriction and Prostate Cancer 
 The concept of caloric restriction, or limiting ones calories by 20-40% of ad libitum 
intake, has been suggested as a method of prolonging longevity across a multitude of species
90,91
. 
As early as 1909, scientists noted that transplanted tumors grew slower when mice were fed a 
calorically restricted diet than diets ad libitum
90
. Evidence from epidemiological studies suggests 
that people who consume fewer calories have a lower incidence of cancer. People living in 
Okinawa Japan, who consume significantly fewer calories than those living on Japan’s mainland, 
have decreased rates of several cancers
92
.  Furthermore, studies on underweight populations 
describe significantly lower cancer rates than the general population
90
. Short-term caloric 
restriction has also been shown to have benefits in cancer outcomes, and has been shown to 
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decrease the adverse effects of chemotherapeutic agents on somatic cells and enhance the 
cytotoxic effects of chemotherapy on cancer cells
91,93
. Short term fasting in cancer patients has 
been shown to be safe and may help reduce side-effects from chemotherapy
93,94
. Caloric-
restriction, while not a new concept, warrants further investigation for cancer 
prevention/treatments.  
Animal Models of Caloric Restriction and Prostate Cancer 
In animal models, caloric restriction has been shown to reduce cancer incidence, improve 
survival, increase apoptosis, reduce proliferation, and decrease tumor burden
90,95
. In Dunning 
R3327-H rats, 20%, 30%, and 40% caloric restriction significantly reduced tumor growth 
without inducing malnutrition
95
. Furthermore, caloric restriction resulted in a less aggressive 
phenotype in tumor morphology, increased tumoral apoptosis, and a reduction in tumoral 
angiogenesis
95
. In the TRAMP model of PCa, a 20% caloric restriction beginning at puberty at 7 
weeks of age significantly reduced tumor incidence at 11 and 20 weeks of age
96
. Interestingly, a 
20% caloric restriction was still effective in reducing epithelial lesions when initiated at 20 
weeks of age, though to not as great of an extent as restriction at puberty
97
. Intermittent caloric 
restriction beginning at 7 weeks of age resulted in an even greater reduction in cancer incidence 
than chronic caloric restriction
98
. Together, rodent studies suggest that caloric restriction 
suppresses PCa in rodent models.   
Pro-Inflammatory Cytokines and Prostate Cancer 
Infiltration by inflammatory cells into tumors was once thought as the immune system’s 
best attempt at eradicating them
99
. Recent evidence shows that the presence of inflammatory 
cells contribute to tumor development and progression
99
. Tumor–associated macrophages secrete 
angiogenic factors, cytokines, metalloproteinases, and other factors that contribute to tumor 
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growth and progression. Contributors to inflammation include interleukin-1β (IL-1β), 
interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), interferon-γ (IFN-
γ), and interleukin-17 (IL-17). Elevated serum levels of IL-6 have been associated with 
metastatic PCa
100
, but IL-6 has been suggested to play a major role in the early stages of PCa 
development as well
101
. IL-6 may act as a growth factor and protect PCa cells from 
chemotherapeutic agents
100
 and has been shown to activate expression of AR in DU145 and 
LNCaP PCa cells
102
. Treatment with a monoclonal antibody to IL-6 improves prognosis in 
patients with advanced stage PCa
103
. TNF-α is a major pro-inflammatory cytokine that is 
secreted in the tumor micro-environment
104
. An increase in prostatic TNF-α expression was 
associated with adverse prognostic factors after prostatectomy
104
.  
IL-1β is a multifunctional pro-inflammatory cytokine which has been shown to inhibit 
proliferation, reduce PSA, and reduce AR levels in LNCaP cells
105,106
. IL-1β exerts some of its 
biological actions by activating the transcription factor, NF-κB105. IL-17 produced by tumor-
infiltrating lymphocytes has been implicated in tumor vascularization of cervical
107
 and ovarian 
cancers
108
. IL-17 has also been suggested to promote the growth of prostate tumors from PIN
109
 
and promote the development of CRPC in transgenic mice
110
. IL-10 has been suggested to 
modulate tumor growth and angiogenesis
111
. IL-10, an anti-inflammatory cytokine, has been 
shown to down-regulate levels of IL-6 and play an important role in the balance of cytokines in 
PCa
112
. IL-10 production from cells transfected with IL-10 cDNA resulted in the down-
regulation of VEGF, IL-1β, IL-6, and MMP-9 in activated macrophages which normally 
infiltrate tumors
113
. In contrast, high circulating levels of IL-10 and IL-6 have been correlated 
with advanced progression and morbidity in patients with CRPC
112
. The dual actions of IL-10 
appear to be related to cancer stage and are important to understand. Interferons have been 
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proposed as the ideal tumor suppressor because they are specific in differentiating normal cells 
from neoplastic cells
114
. IFN-γ activates the JAK-STAT pathway which can lead to the 
transcription of genes suggested to be important tumor suppressors
114
. IFN-γ inducible genes 
which are located on the 10q 23-26 and 17q 21 chromosomal loci regions are deleted in 30% of 
PCa cases
114
. Additionally, IFN-γ has been found to increase apoptosis and decrease tumor 
volumes in murine models of PCa
114
.   
Isoflavones have been shown to affect pro-inflammatory cytokines in vivo and in vitro
115
. 
Genistein reduced serum expression of TNF-α and IL-6 in rats with non-alcoholic 
steatohepatitis
116
, and an isoflavone-enriched soy protein diet reduced serum TNF-α and IL-1β in 
Zucker rats
117
. In humans, consumption of soy nuts significantly reduced serum levels of TNF-α, 
but not IL-6
115
. Genistein has been shown to reduce expression of IL-1β, TNF-α in LPS-treated 
microglial cells
118
.  Other studies using purified isoflavones in vitro have shown mixed results on 
serum levels of pro-inflammatory cytokines
115,119
. There is a need to investigate soy germ and its 
constituents for the potential to reduce pro-inflammatory cytokines involved in prostate 
carcinogenesis.  
Aims of Dissertation  
 There is considerable evidence describing the health benefits of carotenoids. However, 
when carotenoid-containing foods are consumed as part of a meal, the interactions with other 
nutrients in the meal can inhibit or enhance the bioavailability of carotenoids. Co-consumption 
with dietary fat has been shown to enhance the bioavailability of carotenoids; however, the fat 
type (saturation, chain length, etc.) is an important factor to consider as not all fats have the same 
health benefits. The specific aim for this portion of the thesis is to: 
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1) Determine the bioavailability of tomato carotenoids when consumed with fat sources of 
varying saturation and chain length. 
There is a growing body of evidence that suggests tomato and soy bioactives may reduce 
the risk of PCa. The slow-growing nature of most PCa’s coupled with the long latency period 
between diagnosis and medical treatment provides an excellent window for dietary interventions 
to be effective in preventing the progression of PCa. The overall hypothesis of this project is that 
dietary bioactives from whole tomato products and from soy germ can reduce the incidence of 
PCa. The specific aims of this portion of the thesis are to: 
2) Examine the efficacy of a standard TP to reduce the risk of PCa when administered as an 
intervention in a pre-clinical rodent model.  
3) Determine the efficacy of whole soy germ, daidzein, and equol on the incidence of PCa 
in a pre-clinical rodent model.  
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CHAPTER 2 
Coconut Oil Enhances Tomato Carotenoid Tissue Accumulation Compared to Safflower 
Oil in the Mongolian Gerbil (Meriones unguiculatus)
 1 
ABSTRACT 
Evidence suggests that monounsaturated and polyunsaturated fats facilitate greater 
absorption of carotenoids than saturated fats. However, the comparison of consuming a 
polyunsaturated fat source versus a saturated fat source on tomato carotenoid bioaccumulation 
has not been examined. Our goal was to determine the influence of coconut oil and safflower oil 
on tomato carotenoid tissue accumulation in Mongolian gerbils (Meriones unguiculatus) fed a 
20% fat diet. Coconut oil feeding increased carotenoid concentrations among many 
compartments including total carotenoids in the serum (p=0.0003), adrenal glandular phytoene 
(p=0.04), hepatic phytofluene (p=0.0001), testicular all-trans lycopene (p=0.01), and cis-
lycopene (p=0.006) in the prostate-seminal vesicle complex compared to safflower oil. Safflower 
oil-fed gerbils had greater splenic lycopene concentrations (p=0.006) compared to coconut oil-
fed gerbils. Coconut oil feeding increased serum cholesterol (p=0.0001), and decreased hepatic 
cholesterol (p=0.0003) compared to safflower oil. In summary, coconut oil, enhanced tissue 
uptake of tomato carotenoids to a greater degree than safflower oil. These results may have been 
due to the large proportion of medium chain fatty acids in coconut oil which might have caused a 
shift in cholesterol flux to favor extrahepatic carotenoid tissue deposition.  
 
 
1
 Adapted with permission from Conlon LE, King RD, Moran NE, Erdman JW, Jr. J Agric Food 
Chem 2012;(60):8386-8394. Copyright 2012 American Chemical Society.
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INTRODUCTION 
Tomato consumption has been linked to decreased chronic disease risk
1
. In addition to 
vitamins and minerals, tomatoes contain a variety of carotenoids. Lycopene is the major 
carotenoid found in tomatoes, but tomatoes also contain phytoene, phytofluene, α-carotene, ζ-
carotene, and β-carotene1. Lycopene has garnered much interest because of its ability to quench 
singlet oxygen, attenuate LDL levels, reduce the risk of cardiovascular disease, and potentially 
inhibit carcinogenesis
2,3
. However, the other tomato carotenoids may exhibit similar bioactive 
properties as lycopene
1
. Recent studies have suggested that the combination of tomato 
carotenoids from whole tomato powder (TP) may be more effective in disease prevention than 
lycopene alone
1,4
.  
Bioavailability describes the degree to which carotenoids may be absorbed and utilized 
from ingested food sources
2
. Many factors influence carotenoid bioavailability. The species of 
carotenoid, food matrix, food processing, amount of carotenoid consumed, genetic factors, and 
nutrient interactions as well as the co-consumption of dietary fat are all contributing factors
2
. The 
latter point was demonstrated in humans when carotenoids from a vegetable salad were more 
bioavailable when consumed with a full-fat salad dressing than with a reduced-fat salad 
dressing
5
. Additionally, tomato carotenoids were more readily absorbed from salsa and salad 
with the addition of avocado oil or avocado fruit
6
. Dietary fat is believed to facilitate 
bioavailability at the levels of solubilization, micellarization, and chylomicron packaging of 
dietary carotenoids
6–8
. 
The structural properties of dietary fat also influence carotenoid bioavailability with 
evidence suggesting fats with differing degrees of saturation differ in their ability to enhance 
carotenoid absorption. In humans, saturated fat-rich beef tallow increased post-prandial β-
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carotene content in chylomicrons compared to polyunsaturated fat-rich sunflower oil
9
. However, 
butter, a source of saturated fat, reduced the post-prandial chylomicron response in humans when 
compared with monounsaturated olive oil and polyunsaturated sunflower oil
10
. These studies 
suggest that monounsaturated and polyunsaturated fats enhance secretion of chylomicrons, while 
saturated fat enhances carotene incorporation into chylomicrons. The specific effects, however, 
of a saturated vs. polyunsaturated fat on tomato carotenoid incorporation into chylomicrons has 
not been previously reported.  
Previous studies have indicated that fatty acid chain length may also influence carotenoid 
bioavailability and absorption. Borel et al. demonstrated increased solubility of carotenoids as 
fatty acid chain length decreased
8
. Lycopene and β-carotene were more soluble in tricaprylin, a 
source of medium chain triglycerides, when compared to long chain triglycerides from fish oil
8
. 
Incorporation of carotenoids into mixed micelles was enhanced by the addition of long chain 
fatty acids in vitro when compared to medium chain fatty acids
11
. However, carotenoid uptake 
into Caco-2 cells was not impacted by fatty acyl composition of mixed micelles
11
, suggesting 
triglyceride chain length does not affect carotenoid uptake by enterocytes. Furthermore, 
absorption of β-carotene was similar when medium chain triglycerides and long chain 
triglycerides were compared in the perfused, isolated rat intestine
12
. Borel et al. also observed an 
increase in β-carotene in chylomicrons when humans ingested a salad with long chain 
triglycerides compared to medium chain triglycerides
13
. In short, while medium chain 
triglycerides are better at solubilizing lycopene and β-carotene than long chain triglycerides, 
human and animal trials suggest long chain fatty acids may facilitate micellarization and 
incorporation of carotenes into chylomicrons. Intestinal absorption of carotenes does not seem to 
be significantly impacted by fatty acid chain length. While these reports describe the impact of 
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fatty acid chain length and saturation on specific underlying steps of carotenoid bioavailability, 
there is little reported on the summative outcome of these altered mechanisms in terms of 
resultant serum and tissue carotenoid concentrations in response to differing consumed fat types.  
Epidemiological evidence suggests regular intake of carotenoid-containing foods, such as 
fruits and vegetables, may decrease the risk for certain cancers
3
. A consequence of increased 
bioavailability may be increased bioaccumulation. Tissues with increased carotenoid 
bioaccumulation may offer some enhanced protection against oxidation and/or other events that 
lead to cancer.  
The Mongolian gerbil (Meriones unguiculatus) has been shown to absorb β-carotene and 
lycopene intact
14
. In addition we have reported that other tomato carotenoids, phytoene and 
phytofluene, have marked accumulation in liver, spleen, lungs, testes, adrenal glands, the 
prostate-seminal vesicle complex, and adipose tissues
15
. The Mongolian gerbil is an excellent 
model for studies involving carotenoid bioaccumulation because it accumulates tomato 
carotenoids in levels proportionate to humans
15
.  
Previously, we have fed 10% TP diets to mice, rats, and gerbils
4,15–17
. Gerbils fed a 10% 
TP diet for 26 days followed by a 2 day wash-out period, had serum lycopene levels of 0.007 
μmol/dL15. Higher serum lycopene concentrations have been observed in men ages 19-50 years 
old with an average serum lycopene concentration of 0.05 μmol/dL18. Therefore, a 10% TP 
rodent diet can be utilized based upon having similar physiologically relevant serum lycopene 
concentrations to those seen in humans. 
 
In addition to carotenoid accumulation, the lipoprotein profiles of the gerbil are more 
similar to humans than most other rodents, making carotenoid metabolism findings more 
relevant than those results in other species
19
. A variety of fats have been successfully fed to 
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gerbils to study lipid metabolism. In particular, two very different fats, saturated coconut oil and 
polyunsaturated safflower oil were previously fed to gerbils to study lipoprotein metabolism
20,21
. 
Coconut oil is a good source of medium chain triglycerides commonly used in enteral feeding 
solutions for humans
22
. Safflower oil is a common polyunsaturated fat used for cooking and as 
an ingredient in salad dressings
23
. 
How fatty acid chain length impacts the absorption and bioaccumulation of the array of 
tomato carotenoids, including phytoene, phytofluene, ζ-carotene, β-carotene, and lycopene, from 
tomatoes has not been determined. We chose coconut oil and safflower oil to study carotenoid 
lipid metabolism because of the use of these fats in previous studies
20,21
 and the differing fat 
characteristics which may impact carotenoid accumulation. Therefore this work compares the 
effect of medium chain triglyceride-rich coconut oil vs. long chain triglyceride-rich safflower oil 
on tissue bioaccumulation of tomato carotenoids from whole TP in Mongolian gerbils.  
MATERIALS AND METHODS 
 Chemicals. The HPLC-grade solvents, hexane, methanol, dichloromethane, methyl-tert 
butyl ether (MTBE), and chloroform were purchased from Fisher Scientific (Pittsburg, PA). 
Potassium hydroxide and ammonium acetate were purchased from Fisher Scientific. Ethanol and 
polyoxyethylene octylphenyl ether were purchased from Sigma-Aldrich (St. Louis, MO). 
Phytoene, phytofluene, and ζ-carotene standards were purchased from Carotenature (Lupsingen, 
Switzerland). Lycopene and β-carotene were extracted from lycopene or β-carotene beadlets and 
obtained from DSM (Heerlen, Netherlands).  
 Animal Methods. The University of Illinois Institutional Animal Care and Use Committee 
(IACUC) approved all procedures with animals. Forty-day-old male Mongolian gerbils were 
obtained from Charles River Laboratory (Wilmington, MA) (n=40) and were fed a pelleted chow 
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diet for a 2-day acclimation period. On day 3, gerbils were randomized to either one of two 
control diets (n=10/dietary treatment). Diets were modified from previously used high fat gerbil 
diets
19
 and those used to deliver TP in the diet to rodents
15
 (Table 2.1). Control diets consisted of 
20% safflower oil (SOC) or 18% coconut oil, with 2% safflower oil (COC) to prevent essential 
fatty acid deficiency
24
. Experimental diets consisted of 20% safflower oil with 10% TP (TPSO) or 
18% coconut oil and 2% safflower oil with 10% TP (TPCO). TP contributed lycopene, β-
carotene, phytoene, phytofluene, and ζ-carotene to the diet (Table 2.2). The fatty acid profile for 
each diet is outlined in Table 3. Coconut oil consisted of 42.5% lauric (C12:0), 15.8% myristic 
(C14:0), and 8.9% palmitic acids (C16:0). Minor components in coconut oil included oleic acid 
(C18:1) (7.8%), and linoleic acid (C18:2) (9.3%). The fatty acid profile of safflower oil consisted 
of 67.8% linoleic acid, and 17.2% oleic acid. Minor contributors included 6.4% palmitic acid 
(C16:0) and 2.6% stearic acid (C18:0) (Table 2.3). All gerbils were fed 15 g of the respective diet 
every two days for 28 days. Gerbil weights were recorded every two days throughout the study to 
monitor health and growth. On day 30, all four groups were fasted for approximately 4-6 hours 
before being sacrificed. Gerbils were anesthetized with CO2, blood was collected via cardiac 
puncture and gerbils were then euthanized via CO2 asphyxiation. Following euthanization, 
animals were partially shaved and ventral skin samples were taken from each animal. Skin, 
gonadal adipose, heart, lungs, testes, adrenal glands, and prostate seminal vesicle complex were 
removed, weighed, flash frozen in liquid nitrogen and stored at -80 °C for future analysis. 
Additionally, livers were perfused with ice cold 1.15% potassium chloride (KCl) before being 
frozen and stored.   
Dietary Carotenoid Extraction. To verify dietary carotenoid content, the entire 
extraction procedure was performed underneath yellow light along with other general 
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precautions taken to preserve carotenoids. The extraction method used has been previously 
described
16
. First, 0.025 g of powdered diet was suspended in 5 mL of ethanol containing 0.1% 
butylated hydroxytoluene (BHT). Samples were homogenized at level 3 (Power Gen 500, Fisher-
Scientific, Pittsburg, PA) for 120 s and 1 mL of saturated potassium hydroxide (KOH) solution 
was added. Samples were saponified in a 60 °C water bath with intermittent vortexing for 30 
min, were removed, and 2 mL of deionized water and 6 mL of hexanes were added for biphasic 
extraction of carotenoids. Samples were vortexed, separated by centrifugation for 10 minutes and 
the organic hexanes phase was removed and reserved. The addition of hexanes, followed by 
separation and removal was repeated two more times. Hexanes were pooled and concentrated 
using a Speedvac concentrator (Speedvac model AS160, Savant, Milford, MA).  Samples were 
stored under argon at -20 °C for less than 48 hours before HPLC analysis.  
Tissue Carotenoid Extraction. Liver carotenoid concentrations were determined by 
extracting approximately 0.1 g of liver tissue. Whole spleen (~ 0.07 g) and prostate-seminal 
vesicle complex (~ 0.4 g) were extracted for each animal. For adrenal glands (~ 0.03 g), testes (~ 
1.1 g), and lungs (~ 0.4 g), both specimens were pooled and extracted together for each animal. 
Samples were added to 5 mL of ethanol containing 0.1% BHT followed by manual 
homogenization. Carotenoids were extracted by hexanes using the above-described protocol.  
Skin Carotenoid Extraction. Subcutaneous fat was removed prior to the extraction. The 
skin extraction procedure was previously described
25
. Briefly, ~ 0.3 g of skin was flash frozen 
and ground into a fine powder, then 1 mL of ethanol with 0.1% BHT, 1 mL of water, and 5 mL 
of hexane/dichloromethane (5:1, v/v) were added to the samples. The samples were mixed and 
the top layer of hexane and dichloromethane was removed. The extraction was repeated and both 
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hexane and dichloromethane extractions were pooled and dried under argon gas. Samples were 
stored at -20 °C for less than 24 hours before analysis.  
HPLC Analysis. Samples were analyzed using high-pressure liquid chromatography – 
photodiode array detector system (HPLC-PDA, Waters, Milford, Ma). A C30 reversed phase 
column (4.6 x 150 mm, 3 μm, YMC, Wilmington, NC) cooled to 18 °C was used with MTBE, 
methanol, and 1.5% (w/v) aqueous ammonium acetate mobile phases to separate phytoene, 
phytofluene, lycopene, ζ-carotene, and β-carotene. Specific mobile phase compositions and 
gradient elution method were used as described previously
26
. Extracts of all tissues, except for 
the liver were reconstituted in 40 μL of MTBE. Liver extracts were reconstituted in 300 μL of 
MTBE. Twenty-seven μL of the sample reconstituted in MTBE was injected for each tissue or 
diet for carotenoid analysis. Carotenoids were identified and quantified via UV spectra, retention 
times and standard comparison. Phytoene, phytofluene, and ζ-carotene standards were purchased 
and lycopene was extracted from 10% Redivivo beadlets. β-carotene was extracted from 15% 
beadlets. Samples were analyzed within 48 hours of extraction. Samples were kept at 4 °C on an 
autosampler cooling tray and handled under yellow light to reduce carotenoid degradation. 
 Hepatic Lipid Extraction. Total liver lipids were extracted following the Folch 
method
27
. Briefly, 0.5 g of tissue was homogenized in a solution of chloroform: methanol (1:1). 
A 0.29% sodium chloride (NaCl) solution was added to promote phase separation, followed by 
centrifugation. Chloroform was added followed by centrifugation and addition of NaCl solution. 
This step was repeated twice. Supernatant was retained after each of the steps, pooled into pre-
weighed tubes, and evaporated in a fume hood for approximately 48 hours, before being stored 
in a desiccator for 24 hours. Samples were then weighed to determine total lipid concentration.  
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Serum and Hepatic Cholesterol Analysis. Serum total cholesterol concentrations were 
quantified using Wako Cholesterol E enzymatic colorimetric assay (Wako Chemicals, 
Richmond, VA). The protocol was modified to the manufacturer’s microtiter procedure, using 3 
µL of serum per analysis (Wako Chemicals, Richmond, VA). Hepatic cholesterol concentrations 
were determined by reconstitution of extracted hepatic lipids in isopropyl alcohol containing 
10% polyoxyethylene octylphenyl ether. All standards were diluted with the same extraction 
solution and the remainder of the analysis was performed following the manufacturer’s protocol.  
Fatty Acid Analysis. Fatty acid analysis was previously described
28
. Briefly, 0.1 g of 
diet was weighed and 2 mL of a dilute internal standard, tridecanoic acid, was added. 
Methanolic-HCl was added and the samples were incubated at 100 °C for an hour. Two mL of 
hexanes and 5 mL of potassium carbonate were slowly added to each tube and the samples were 
vortexed and centrifuged. The top organic layer was collected, dried under nitrogen gas, and 
protected from light. The samples were then transferred to gas chromatography vials and 
analyzed using gas chromatography as previously described
28
.  
Statistical Analyses. Tissue carotenoid concentrations in the safflower oil + TP and 
coconut oil + TP groups were compared using ANOVA, and significant differences were 
detected using Tukey’s Studentized test (α=0.05) when the assumptions of ANOVA were met. 
When the assumptions of ANOVA were not met, the Wilcoxon test was used to detect 
differences (α=0.05). Statistical analysis was performed using SAS v. 7.1 (SAS Institute Inc., 
Cary, NC). Data are reported as mean ± standard error of the mean (SEM). 
RESULTS 
Body Weight and Food Intake. The final weight of gerbils at sacrifice did not differ by 
dietary treatment group (p=0.41) with an average gerbil weight of 69.6 ± 0.8 g. Additionally, the 
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final weight of gerbil livers did not differ by dietary treatment (p=0.15). When compared as 
percent of body weight, there were some minor organ weight differences between groups. The 
final weight of gonadal-adipose tissue were different between the safflower oil + TP-fed and 
coconut oil-fed dietary groups (p=0.03), with an average weight of 0.90 ± 0.05 g and 0.68 ± 0.05 
g, respectively. The final weight of the testes was greater (p=0.02) in the safflower oil + TP-fed 
group 1.15 ± 0.03 g, compared to the other dietary groups 1.07 ± 0.02 g. Safflower oil-fed 
animals had greater (p=0.04) adrenal glandular weights (0.05 ± 0.001 g) compared to coconut 
oil-fed animals (0.038 ± 0.001 g). In short, gonadal adipose, testes, and adrenal glandular 
weights were significantly greater in safflower oil-fed animals which might suggest greater 
accumulation of fat in these tissues. These fat-specific findings have not been previously 
reported.  
Diet Carotenoid Profile. Lycopene was also the most prevalent carotenoid in the TP; 
accounting for over 90% of the total carotenoid content (Table 2.2).The TP diet also contained 
phytoene, phytofluene, ζ-carotene, and β-carotene.  
 Tissue Carotenoid Accumulation. Lycopene was the dominant carotenoid in the liver, 
spleen, testes, lung, serum, and skin. Phytoene was the most abundant carotenoid in the adrenal 
glands. There was no accumulation of phytoene in the androgen-sensitive tissues, the testes or 
prostate-seminal vesicle complex. Coconut oil feeding increased pulmonary phytofluene 
(p=0.006) and ζ-carotene (p=0.003), adrenal glandular phytoene (p=0.05), hepatic phytoene 
(p=0.02) and phytofluene (p=0.0001), and testicular phytofluene (p=0.01), cis-lycopene (p=0.01), 
all-trans lycopene (p=0.010), total lycopene (p=0.01) and ζ-carotene (p=0.02). Coconut oil 
feeding also increased phytofluene (p=0.008), cis-lycopene (p=0.006), and ζ-carotene (p=0.005) 
in the prostate-seminal vesicle complex. The prostate-seminal vesicle complex (p=0.01), testes 
42 
 
(p=0.01), and serum (p=0.0003) had greater total carotenoid concentrations in animals fed 
coconut oil (Table 2.4). Safflower oil-fed gerbils had greater splenic all-trans lycopene (p=0.03), 
and total lycopene (p=0.006) compared to coconut oil-fed animals.  
 To our knowledge, this is the first time tomato carotenoids have been reported in skin from 
Mongolian gerbils (Table 2.4). All-trans lycopene and cis-lycopene were consistently detected in 
skin in quantifiable amounts, but differences between groups were not significant (p=0.17) and 
(p=0.38) respectively. Phytoene and phytofluene were detected in skin in fewer than 50% of the 
animals. Phytoene and phytofluene were considered detectable, but unquantifiable if HPLC 
signals corresponded with carotenoid concentrations in the injection carrier solvent of less than 
0.2 nM. In the skin, ζ-carotene and β-carotene were detected in fewer than 20% of the animals. 
When detected, ζ-carotene and β-carotene were in amounts below the level of quantification (0.9 
nM ζ-carotene, 0.1 nM β-carotene in the HPLC carrier solvent). β-carotene was detected but 
unquantifiable in most other tissue extracts. An unidentified compound was found in the skin of 
animals fed TP diets and in those fed control diets. The compound had a similar retention time 
and maximum absorbance (282.8 nm) to the phytoene standard (286 nm). However, upon closer 
inspection, the compound did not have the characteristic spectral fine structure of phytoene 
determined by comparison to phytoene standards
29
. Therefore this compound was determined not 
to be phytoene. 
Hepatic Lipids. Total hepatic lipid concentrations did not differ by dietary treatment 
group (p=0.9) with an average concentration of 37 ± 0.8 mg/g for all groups. 
Serum and Hepatic Cholesterol. Animals fed coconut oil diets maintained significantly 
higher serum cholesterol concentrations (178 ± 8.2 mg/dL) than animals fed safflower oil diets 
(82 ± 6.7 mg/dL) (p=0.0001) (Figure 2.1). In the current study, animals fed safflower oil had 
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significantly higher (p=0.0003) hepatic cholesterol concentrations (4.0 ± 0.2 mg/g) compared to 
coconut oil fed groups (2.7 ± 0.14 mg/g) (Figure 2.2). TP addition to either safflower or coconut 
oil diets did not alter hepatic cholesterol concentrations (p=0.4 and p=0.37, respectively).  
DISCUSSION 
The aim of this study was to compare the effects of an oil high in medium chain saturated 
fatty acids (coconut oil) with an oil high in long chain polyunsaturated fat (safflower oil) on 
tomato carotenoid tissue accumulation in gerbils. We observed enhanced tissue bioaccumulation 
of tomato carotenoids in all tissues from animals fed coconut oil except for the spleen and skin as 
well as differential tissue accumulation between carotenoids unrelated to dietary fat among the 
tissues measured.  
 Carotenoids are bioactive molecules with antioxidant capabilities and may function to 
reduce the risk for certain chronic diseases and cancers
3
. Lycopene, phytoene, and phytofluene 
have been shown to accumulate in a variety of human and animal tissues including liver, adrenal 
glands, testes, kidney, pancreas, breast, skin, ovary, spleen, and prostate
1,3
. In the current study, 
tissue concentrations of phytoene, phytofluene, cis-lycopene, all-trans lycopene, ζ-carotene, and 
β-carotene were quantified in liver, lungs, spleen, adrenal glands, testes, prostate-seminal vesicle 
complex, serum, and skin (Table 2.4).  
 Previously, we have shown that tomato carotenoids differentially accumulate in both male 
Fisher 344 rat and Mongolian gerbil tissues in levels disproportionate to those fed in the diet
15,16
. 
In the current study, lycopene was the dominant carotenoid in the liver, spleen, testes, lung, 
serum, and skin. Lycopene was also the most prevalent carotenoid in the TP, accounting for over 
90% of the total carotenoid content (Table 2.2). Phytoene was the most abundant carotenoid in 
the adrenal glands accounting for 62% of total carotenoids in the coconut oil-fed and 45% in the 
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safflower oil-fed adrenal glands, despite the fact that phytoene concentrations in the diet 
contributed only 2% of the total carotenoids. These results suggest tissue-specific uptake or 
metabolism of tomato carotenoids consistent with reports from our previous studies
15,16
. Similar 
to findings by Engelmann, there was no accumulation of phytoene in the androgen-sensitive 
tissues, which suggests a difference in absorption or metabolism of phytoene in these tissues
15
.  
 Tissue accumulation of carotenoids was affected by type of fat consumed with coconut oil 
increasing carotenoid accumulation in almost every tissue except for the spleen and skin. Splenic 
lycopene was significantly increased by the safflower oil diet. Previous studies have observed 
carotenoid accumulation levels in the spleen to be relatively high compared to other tissues
15
. The 
spleen is important for immune function because it removes bacteria and debris from the 
bloodstream
29
. However, carotenoid enrichment of the spleen is poorly understood.  
We observed differences in carotenoid accumulation by dietary fat type in the prostate-
seminal vesicle complex. Phytofluene was the dominant carotenoid in the prostate-seminal 
vesicle complex of the coconut oil-fed animals accounting for 50% of the total carotenoids. In 
contrast, lycopene was the dominant carotenoid in the prostate-seminal vesicle complex of the 
safflower oil-fed animals accounting for 57% of the total carotenoids. Engelmann observed 
lycopene as the dominant carotenoid in the prostate-seminal vesicle complex when gerbils were 
fed cottonseed oil, which contains a mixture of saturated, monounsaturated, and polyunsaturated 
fat
15
. This suggests lycopene accumulation in the prostate-seminal vesicle complex is dependent 
on the type of fat consumed. Polyunsaturated fats may enhance lycopene accumulation in the 
prostate-seminal vesicle complex, while saturated fat from coconut oil, enhances total carotenoid 
accumulation in the prostate-seminal vesicle complex with phytofluene being the major 
carotenoid deposited.  
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The testes of the coconut oil-fed animals had greater total lycopene concentrations, but 
weighed significantly less than those of the safflower oil-fed animals. Studies using carotenoid 
metabolizing enzyme knockout mice have shown that dietary lycopene and TP reduce testicular 
testosterone which might explain alterations in growth of the testes
17
.  
To evaluate if the change in carotenoid tissue deposition was a result of a change in 
cholesterol and lipid metabolism, serum and hepatic cholesterol and hepatic lipids were 
quantified. Animals fed coconut oil diets had significantly higher serum cholesterol 
concentrations than animals fed safflower oil diets (Figure 2.1). Coconut oil is known to 
increase serum cholesterol in humans due to its high amounts of lauric (C12:0), myristic (C14:0) 
and palmitic (C16:0) acids
30
. The primary fatty acid in coconut oil, lauric acid, accounted for 
42% of the fatty acids in the diet of the coconut oil-fed animals (Table 2.3). The combination of 
these three cholesterol-raising fatty acids in coconut oil likely contributed to the increased serum 
cholesterol in the current study.  
In the current study, animals fed safflower oil had significantly higher (p=0.0003) hepatic 
cholesterol concentrations compared to coconut oil fed groups (Figure 2.2). This finding is 
consistent with other studies showing that polyunsaturated fats increase hepatic cholesterol 
uptake
31,32
. In contrast to coconut oil, safflower oil is composed of long chain polyunsaturated 
fatty acids, primarily linoleic acid (C18:2) (Table 2.3).  
Saturated fats have long been grouped together for dietary recommendations, but they 
may not all have the same biological impact. Coconut oil is a unique saturated fat because of its 
fatty acid profile. The fatty acid profiles of saturated fats can be dramatically different; for 
instance butter is primarily composed of short chain fatty acids, coconut oil is primarily medium 
chain fatty acids, and beef tallow consists of long chain fatty acids
23
. Studies comparing coconut 
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oil to other saturated fats have conflicting results concerning serum cholesterol. When coconut 
oil and beef tallow were compared in humans, coconut oil increased serum LDL and total 
cholesterol relative to beef tallow
33
. Similarly, long chain saturated fatty acids fed to guinea pigs 
resulted in decreased plasma LDL concentrations when compared to coconut oil
34
. However, 
butter significantly increased LDL and total cholesterol levels when compared to coconut oil in 
moderately hypercholesterolemic adults
35
. Differences in saturated fatty acid chain length might 
account for differences in LDL metabolism and LDL receptor synthesis; therefore we cannot 
categorize the effect of all saturated fats on plasma cholesterol based on fatty acid saturation 
alone. 
 The composition of fatty acids in oils can alter carotenoid solubulization, micellarization, 
absorption, and chylomicron formation. While in the current study, carotenoid absorption was 
not measured directly, fatty acid chain length does not appear to contribute to differences in 
carotenoid absorption when comparing different fats
12
. In the current study, carotenoid tissue 
accumulation was increased in animals fed coconut oil. Previously, Borel et al. observed 
increased solubility of carotenoids with decreasing fatty acid chain length
8
. Carotenoids are 
lipophilic compounds and once released from the food matrix, are solubilized into mixed 
micelles with bile salts. Medium chain fatty acids in coconut oil may cause increased carotenoid 
solubility into mixed micelles compared to the long chain fatty acids from safflower oil. 
Previous studies have indicated increased β-carotene and lycopene micellarization with 
the addition of long chain triglycerides
11
. However, the current study found coconut oil, a source 
of medium chain fatty acids, increased carotenoid tissue deposition when compared to a long 
chain polyunsaturated fat, safflower oil. In contrast to the current study, this previous study used 
tricaprylin as a source of medium chain fatty acids, which is high in caprylic acid (C8:0)
11
. 
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Caprylic acid is shorter than the primary fatty acids found in coconut oil. Relative to tricaprylin, 
longer chain medium chain fatty acids in coconut oil may enhance the carotenoid absorption 
properties to a greater degree than shorter chain medium chain fatty acids and to the same extent 
that long chain fatty acids do. The comparison of different medium chain fatty acids’ effects on 
carotenoid metabolism has not been determined, however, the composition of medium chain 
triglycerides are important because of the potential impact chain length has on micellarization 
and incorporation of carotenoids into chylomicrons.  
Previous studies have shown increased incorporation of β-carotene and lycopene into 
chylomicrons when long chain triglycerides were used
13
. However, in the current study, coconut 
oil facilitated carotenoid tissue accumulation to a greater degree than safflower oil. Because 
coconut oil is composed of medium chain fatty acids, these fatty acids can bypass chylomicron 
formation and be absorbed directly by the portal vein
13
. This results in decreased post-prandial 
chylomicron formation with medium chain fatty acids
13
. Additionally, it has been described that 
medium chain triglycerides can be incorporated into chylomicrons when they are the only source 
of fat in the diet
36
. In the current study, gerbils were fed a 20% fat diet of 18% coconut oil and 
2% safflower oil or 20% safflower oil. The high amount of medium chain triglycerides in 
coconut oil may have facilitated incorporation into mixed micelles and absorption by 
enterocytes, however the mechanism of carotenoid absorption is unclear.  
We observed increased tissue accumulation of tomato carotenoids in every tissue 
measured except for the spleen and skin in animals fed coconut oil. Chylomicrons are eventually 
transported to the liver as chylomicron remnants where hepatic metabolism of carotenoids can 
occur
17
. In the liver, carotenoids are repackaged into very low-density lipoproteins (VLDL) and 
released into circulation where they have access to peripheral tissues. While in circulation, 
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VLDLs lose triglycerides and become denser lipoproteins: intermediate-density lipoprotein 
(IDL) and low-density lipoprotein (LDL). LDLs and IDLs are returned to the liver where 80% of 
the LDL is catabolized
37
. Saturated fats can interrupt this cycle by reducing hepatic uptake of 
LDL
38,39
. The primary fatty acids in coconut oil (lauric, myristic and palmitic acids) reduce LDL 
receptor activity
30,39
.  thus increasing serum cholesterol and leaving more LDL free to re-
circulate to peripheral tissues. Non-polar carotenes, specifically lycopene, are carried primarily 
in the LDL fraction of lipoproteins
40
. In the current study, serum cholesterol in the coconut oil-
fed animals was significantly increased and hepatic cholesterol was significantly decreased when 
compared to safflower oil-fed animals. Perhaps a coconut oil-mediated change in LDL levels 
altered the flux of carotenoids between the liver and peripheral tissues resulting in increased 
tissue-specific accumulation of carotenoids and/or decreased clearance of carotenoids by the 
liver. 
However, when considering the differential accumulation of tissue carotenoids by dietary 
fat (Table 2.4), in tissues enriched with carotenoids by coconut oil feeding, there might be a 
concurrent shift in tissue fatty acid profile to one more similar to that of coconut oil. Perhaps 
tissues that accumulated tomato carotenoids preferentially utilize medium chain fatty acids, and 
as a result of increased tomato carotenoid solubility in medium chain fatty acids
8
, carotenoid 
accumulation was greater. While tissue fatty acid profiles were not measured in the current 
study, studies in dairy cattle have shown that dietary fatty acid manipulation can significantly 
shift the fatty acid profiles of muscle and milk
41
. Further insight into the interaction between 
dietary fat and tissue carotenoid accumulation may be gained by examining tissue fatty acid 
profiles.  
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Carotenoid stability in the diet. Polyunsaturated fats are unstable because their double 
bonds are susceptible to oxidation
38
. To account for possible fat-specific carotenoid degradation, 
carotenoid stability in the diet was measured. Carotenoid content of the diet was measured prior 
to being exposed for 2-days in the animal facility and again after exposure. There was no 
difference in carotenoid content of the diet due to oil type during the 2-day exposure period (data 
not shown). Thus the differences in carotenoid accumulation are not the result of carotenoid 
degradation in the diet.  
In summary, differential accumulation of tomato carotenoids in liver, spleen, lungs, 
adrenal glands, testes, prostate-seminal vesicle complex, serum, and skin was observed 
independent of fat type in the Mongolian gerbil. In addition, we observed fat type-specific effects 
on carotenoid accumulation. Coconut oil feeding resulted in increased tomato carotenoid 
bioaccumulation compared to safflower oil in all tissues measured but the spleen and skin. 
Increased tissue accumulation may have been a result of increased solubility of tomato 
carotenoids in the intestinal lumen, portal absorption of medium chain fatty acids, a cholesterol-
mediated change in the flux of carotenoids between the liver and peripheral tissues, facilitated 
carotenoid cellular uptake by specific fatty acids, or the combination of the four. Research 
investigating the influence of different saturated fats of differing chain lengths on tomato 
carotenoid accumulation and cholesterol flux should be undertaken. It is important to understand 
the differential accumulation patterns of carotenoids in specific tissues and how dietary fats can 
affect these profiles when carrying out animal or human feeding trials with carotenoids.  
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ABBREVIATIONS USED 
COC, coconut oil; TPCO, coconut oil + 10% TP; SOC, safflower oil; TPSO, safflower oil + 10% 
TP; BHT, butylated hydroxytoluene; HPLC-PDA, high performance liquid chromatography-
photodiode array. 
ACKNOWLEDGMENTS 
The authors would like to thank the Division of Nutritional Science at the University of Illinois 
at Urbana-Champaign and the Postdoctoral Peletonia Fellowship for NEM. The authors would 
also like to thank the Khachaturian family for their support of LEC. Dr. Steven Schwartz and 
Rachel Kopec from the Ohio State University provided important advice for the tissue carotenoid 
extractions.  
  
51 
 
FIGURES AND TABLES 
 
Table 2.1. Gerbil Diet Composition Table 
Component 
(g/kg) 
 
18% Coconut Oil 
and 2% Safflower 
Oil Control Diet 
20% 
Safflower 
Oil Control 
Diet 
18% Coconut Oil 
and 2% Safflower 
Oil + 10% TP Diet 
20% Safflower Oil 
+10% TP Diet 
Sucrose 283 283 242 242 
Casein 
a
 200 200 167 167 
Cornstarch 119 119 119 119 
Maltodextrin 94 94 83 83 
Cellulose 60 60 43.8 43.8 
Micronutrients     
Mineral Mix 
b
 35 35 35 35 
Vitamin Mix 
c
 5 5 5 5 
L-cystine 3 3 3 3 
Choline 
Bitartrate 
2.5 2.5 2.5 2.5 
CaHPO4 2 2 2 2 
MgO 1.75 1.75 1.75 1.75 
TP 
d
 
0 0 100 100 
Coconut Oil 180 0 180 0 
Safflower Oil 20 200 20 200 
kcal/g 3.73 3.73 3.73 3.73 
a
 Vitamin-free test casein contains 0.9 g protein/g casein.
 
b
 AIN-93G-MX (Teklad) contains calcium carbonate (12.495 g/kg diet); potassium  phosphate, 
monobasic (6.86 g/kg diet); potassium citrate, monohydrate (2.48 g/kg diet); sodium chloride 
(2.59 g/kg diet); potassium sulfate (1.63 g/kg diet); magnesium oxide (0.85 g/kg diet); ferric 
citrate (0.21 g/kg diet); zinc carbonate (0.06 g/kg diet); manganese carbonate (0.02 g/kg diet); 
cupric carbonate (0.01 g/kg diet); potassium iodate (0.35 mg/kg diet); sodium selenate (0.36 
mg/kg diet); ammonium paramolybdate, tetrahydrate (0.28 mg/kg diet); sodium meta- silicate, 
nonahydrate (0.0575 g/kg diet); chromium potassium sulfate, doceahydrate (9.6 mg/kg diet); 
lithium chloride (0.609 mg/kg diet); boric acid (2.85 mg/kg diet); sodium fluoride (2.22 mg/kg 
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diet); nickel carbonate hydroxide, tetrahydrate (0.111 mg/kg diet); ammonium meta-vanadate 
(0.231 mg/kg diet);  and sucrose (7.73 g/kg diet)
36
. 
c
 AIN-93-VX (Teklad) provides niacin (0.015 g/kg diet); calcium pantothenate (0.008 g/kg   
diet); pyridoxine HCl (3.5 E-3 g/kg diet); thiamin HCl (3 E-3 g/kg diet); riboflavin (3 E-3 g/kg 
diet); folic acid (1 E-3 g/kg diet); biotin (0.1 mg/kg diet); vitamin B12 (0.1% in mannitol) 
(0.0125 g/kg diet); vitamin E, DL-alpha tocopheryl acetate (500 IU/g)  (0.075 g/kg diet); vitamin 
A palmitate (500,000 IU/g) (0.004 g/kg diet); vitamin D3 cholecalciferol (500,000 IU/g) (0.001 
g/kg diet); vitamin K1, phylloquinone (0.375 mg/kg diet); sucrose (4.87 g/kg diet)
36
. 
d
 Drum dried TP (Futureceuticals, Momence, IL) contains 3.68 kcal/g, 0.01 g protein/g, 0.03 g 
fat/g, 0.16 g fiber/g, and 0.52 g carbohydrate/g. 
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Table 2.2. Diet Carotenoid Concentrations (μmol/Kg diet)a    
Diet 
Safflower Oil + 
10% TP 
18% Coconut Oil and 
2% Safflower Oil + 
10% TP 
 Mean ± SEM Mean ± SEM 
Phytoene 12.2 ± 1.6 11.5 ± 1.4 
Phytofluene 5.1 ± 0.6 6 ± 0.3 
cis-Lycopene 86.2 ± 8.8 81 ± 9.1 
all-trans Lycopene 282 ± 47 272 ± 40 
Total Lycopene 368 ± 55 353 ± 49 
ζ-Carotene 1.5 ± 0.09 1.6 ± 0.07 
β-Carotene 1.2 ± 0.5 1.5 ± 0.6 
a
 Diet carotenoid concentrations for 10% TP + 20% safflower oil diet and 10% TP + 18% 
coconut oil and 2% safflower oil. Values represent the mean of diet samples analyzed in 
triplicate ± SEM.  
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Table 2.3. Fatty Acid Analysis of dietary fats 
a 
 
Fatty Acid 
Chain Length 
Common 
name COC 
b 
TPCO 
c 
SOC 
d 
TPSO 
e 
8:0 caprylic 4.7% 3.9% 0.0% 0.0% 
10:0 capric 5.2% 4.9% 0.0% 0.0% 
12:0 lauric 42.9% 42.2% 0.0% 0.0% 
14:0 myristic 15.8% 15.9% 0.2% 0.2% 
16:0 palmitic 8.9% 8.9% 6.3% 6.5% 
18:0 stearic 3.0% 3.1% 2.6% 2.6% 
18:1 oleic 7.7% 7.9% 17.2% 17.1% 
18:2 linoleic 9.0% 9.6% 68.0% 67.5% 
18:3 linolenic 0.1% 0.1% 0.2% 0.2% 
20:0 arachidic 0.1% 0.1% 0.4% 0.3% 
20:1 gondoic 0.1% 0.1% 0.2% 0.2% 
22:0 behenic 0.1% 0.3% 0.0% 0.2% 
Total unidentified FA 2.2% 2.9% 2.7% 3.2% 
Total MCFA 52.8% 51.0% 0.1% 0.1% 
Total LCFA 44.6% 46.0% 95.2% 94.9% 
Total Fatty acids 99.7% 99.9% 98.0% 98.3% 
a
 Table 3 represents the percentage of fatty acids based on total fatty acids in the diet run in 
duplicates. 
b 
COC represents 18% coconut oil and 2% safflower oil  
c 
TPCO represents 18% coconut oil and 2% safflower oil + 10% TP 
d 
SOC represents safflower oil 
e 
TPSO represents safflower oil + 10% TP
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Table 2.4. The Impact of Dietary Fat on Carotenoid Accumulation in Gerbil Tissues 
a 
 
   Tissue 
Dietary 
Treatment 
Group 
Phytoene 
(nmol/g) 
Phytofluene 
(nmol/g) 
cis-Lycopene 
(nmol/g) 
all-trans 
Lycopene 
(nmol/g) 
ζ-carotene  
(nmol/g) 
β-
carotene 
(nmol/g) 
Total 
Lycopene 
(nmol/g) 
Total 
Carotenoids 
(nmol/g) 
Liver SO 
b 
40.4 ± 9.6 a 21.9 ± 4.9 a 47.7 ± 8.7 51.2 ± 13.2 7.7 ± 2.1 3.2 ± 1.6 299.6 ± 113.2 372.7 ± 124.9 
 CO 
c 
61.8 ± 11.0 b 39.6 ± 4.4 b 59.3 ± 10.7 39.5 ± 8.4 8.8 ± 2.2 1.6 ± 0.6 299.1 ± 96.7 410.8 ± 112.3 
Spleen SO 0.001 ± 0.0003 3.8 ± 0.6 17.8 ± 3.4 14.1 ± 2.5 a 0.52 ± 0.15 ND 
d 
22.2 ± 8.8 a 36.3 ± 19.3 
 CO 0.001 ± 0.0003 5.1 ± 0.8 12.4 ± 2.1 0.73 ± 1.2 b 0.78 ± 0.17 NQ 
e 
12.5 ± 4.3 b 25.6 ± 13.2 
Adrenals SO 22.5 ± 8.2 a 10.2 ± 2.5 9.4 ± 2.4 5.4 ± 1.4 2.9 ± 7.7 ND 14.8 ± 9.8 50.4 ± 39 
 CO 71.4 ± 17.9 b 18.3 ± 3.9 14.2 ± 3.1 6.9 ± 1.5 4.6 ± 1.1 ND 21.1 ± 12 115.5 ± 69.8 
Lung SO 0.13  ± 0.01 0.16 ± 0.04 a 0.51 ± 0.17 0.28 ± 0.09 0.06 ± 0.01 a NQ 0.79 ± 0.8 1.1 ± 1.1 
 CO 0.45 ± 0.2 0.42 ± 0.2 b 0.99 ± 0.26 0.44 ± 0.12 0.17 ± 0.03 b NQ 1.4 ± 1.2 2.4 ± 1.8 
Testes SO ND
 
0.2 ± 0.04 a 0.09 ± 0.02 a 0.17 ± 0.03 a 0.03 ± 0.006 a NQ 0.26 ± 0.13 a 0.49 ± 0.23 a 
 CO ND 0.65 ± 0.13 b 0.36 ± 0.08 b 0.57 ± 0.12 b 0.16 ± 0.03 b NQ 0.9 ± 0.65 b 1.7 ± 1.2 b 
Prostate 
Seminal 
Vesicle 
Complex 
SO ND 0.026 ± 0.006 a 0.01 ± 0.002 a 0.025 ± 0.01 0.006 ± 0.002 a ND 0.04 ± 0.04 0.07 ± 0.06 a 
 CO ND 0.086 ± 0.02 b 
0.025 ± 0.003 
b 
0.03 ± 0.004 0.02 ± 0.005 b ND 0.06 ± 0.02 0.17 ± 0.09 b 
Serum 
f
 SO ND ND 0.03 ± 0.002 a 
0.003 ± 0.003 
a 
0.02 ± 0.001 a ND 
0.03 ± 0.005 
a 
0.05 ± 0.12 a 
 CO 0.03 ± 0.006 0.02 ± 0.004 0.04 ± 0.007 b 0.02 ± 0.01 b 0.02 ± 0.004 b ND 0.06 ± 0.01 b 0.1 ± 0.05 b 
Skin SO NQ NQ 0.04 ± 0.02 0.04 ± 0.02 ND ND 0.08 ± 0.04 ------ 
 CO NQ NQ 0.05 ± 0.02 0.05 ± 0.02 ND ND 0.1 ± 0.04 ------ 
a 
Values are means ± the SEM, n=10. Different letters within rows indicate significant differences within tissues (p<0.05).  
b
 SO = Safflower oil + 10% TP.  
c 
CO = coconut oil + 10% TP.  
d 
ND = non detectable within a tissue. 
e
 NQ = not quantifiable within a tissue, but detected at very low levels. 
f
 Units are μmol/dL.
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Figure 2.1. Serum Cholesterol Concentrations 
 
Serum cholesterol concentrations of gerbils fed either a 20% safflower oil diet (SOC; n=10), 
10% TP + 20% safflower oil diet (TPSO; n=10), 18% coconut oil diet + 2% safflower oil (COC; 
n=10), or 10% TP + 18% coconut oil diet + 25 safflower oil (TPCO; n=10), for 28 days. 
Significant differences between safflower and coconut oil diets (α=0.05), are denoted by letters. 
Columns represent the average of 10 analyses performed in triplicate and error bars represent ± 
SEM.  
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Figure 2.2. Hepatic Cholesterol Concentrations 
 
Hepatic cholesterol concentrations of gerbils fed 20% safflower oil diet (n=10), 10% TP + 20% 
safflower oil diet (n=10), 18% coconut oil + 2% safflower oil diet (n=10), or 10% TP + 18% 
coconut oil + 2% safflower oil diet (n=10), for 28 days.  
Significant differences between safflower and coconut oil diets a (α=0.05), are denoted by 
letters.  
Columns represent the average of 10 analyses performed in triplicate and error bars represent ± 
SEM. 
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CHAPTER 3 
A Low-Lycopene Containing Tomato Powder Diet Intervention Does Not Protect Against 
Prostate Cancer in the TRAMP Model 1 
ABSTRACT 
The Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model develops and 
progresses through all stages of carcinogenesis in a manner similar to humans. Our laboratory 
previously demonstrated a high lycopene tomato powder diet (TP) was effective in reducing 
carcinogenesis in the TRAMP model. The objective of the current study was to determine if a 
low-lycopene TP intervention impacted carcinogenesis at 3 time points. 8-week-old male 
C57BL/6 X FVB TRAMP mice were randomized to consume either an AIN-93G + 10% TP diet 
(N=90) or the AIN-93G control diet (N=88) and assigned to one of three sacrifice ages: 12 
(N=59), 16 (N=60), or 20 (N=59) weeks of age. There was no difference between diets in overall 
cancer incidence at any time point. However, at 16 weeks of age, TP significantly increased 
high-grade PIN (HGP) (p=0.014) and significantly decreased poorly-differentiated (PD) 
(p=0.024) lesions compared to the control diet suggesting a modest reduction in cancer 
progression by TP at 16 weeks of age. Two variables that may explain the modest effect of TP in 
this study were: the amount of lycopene in the TP diet and the timing of the intervention. 
Although the TP diet had 30-fold less lycopene than our previous study, after 8 and 12 weeks of 
feeding, mice had accumulated similar tissue concentrations of carotenoids. In addition, the 
initiation of the diet intervention time of 8 weeks of age instead of 4 weeks of age, may have 
been too late in cancer progression to substantially impact carcinogenesis, as studies have shown 
prostate-specific gene expression changes as early as 8-10 weeks of age in TRAMP mice. This 
study further supports epidemiology data emphasizing lifelong consumption of tomatoes for PCa 
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prevention and suggests that lycopene content of the TP may be critical in reducing PCa in this 
model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 Additional tables and figures not included in this chapter are in Appendix A. 
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INTRODUCTION 
 In 2014, prostate cancer (PCa) remained the second leading cause of cancer deaths in 
U.S. men
1
. Due to increased screening and earlier detection of PCa, recommendations for 
localized PCas often include “watchful waiting” or “active surveillance” which involves frequent 
monitoring of the potential disease progression by digital rectal examination and monitoring of 
PSA levels in an attempt to avoid costly and unnecessary treatments with negative side effects. 
Men diagnosed with PCa often turn to dietary supplements as an inexpensive way to try and 
reduce the risk of cancer progression
2
. 
In 1995, Giovannucci et al. reported that the intake of tomato and tomato-based products 
was associated with a reduction in PCa risk
3
. Lycopene, the predominant carotenoid found in 
tomatoes, has been widely investigated for its effects in PCa. Lycopene has been demonstrated to 
modulate growth factor signaling, cell-cycle programming, angiogenesis, and apoptosis in PCa 
cell lines
4–6
. There have been numerous epidemiology studies examining the effects of lycopene 
and tomato products on PCa risk. Most recently, a high lycopene intake was shown to be 
inversely associated with total PCa and more strongly with lethal PCa in men taking part in the 
Health Professionals Follow-Up Study
7
.  
Results from animal studies examining lycopene, tomato powder (TP), and PCa have 
been promising. In 2003, Boileau et al. determined that consumption of a 10% TP diet reduced 
PCa incidence in N-methyl-N-nitrosurea (NMU)-testosterone-treated rats
8
. Interestingly, they did 
not observe a protective effect in this model when lycopene was provided at the same dose in the 
beadlet form, suggesting that components from the whole tomato, in addition to lycopene, are 
important in preventing carcinogensis
8
. In the Dunning R3327-H rodent model of PCa, a 10% TP 
diet reduced tumor weight and volume compared to the control
9
. Again, the TP diet reduced 
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tumor weight and volume to a greater extent when compared to diets supplemented with 
lycopene beadlets
9
. In two studies using the transgenic adenocarcinoma of the mouse prostate 
(TRAMP) model, a 10% TP diet resulted in a 39% reduction in PCa incidence
10
 and increased 
overall survival compared to control diets
11
. Collectively, these studies suggest that whole 
tomatoes may be more effective than lycopene alone in reducing prostate carcinogenesis.  
Though in vivo studies have produced promising results, they often model lifelong 
consumption of tomato products by beginning the TP diet after weaning. The use of  
complementary and alternative medicine (CAM) and changes in dietary patterns are common in 
cancer patients and in people suffering from chronic diseases
2
. Butler et al., reported that in men 
diagnosed with PCa, 11% reported using CAM beginning at the time of diagnosis for at least 6 
months
2
. Of those, 55% of men reported using dietary supplements and 23% reported dietary 
changes at diagnosis
2
. Therefore, modeling lifelong consumption of lycopene intake may not 
accurately mimic the effects of dietary interventions men adopt following diagnosis of PCa.  
To accurately model a dietary intervention, we initiated a 10% TP diet in TRAMP mice 
at 8 weeks of age when histopathologically-confirmed prostatic intraepithelial neoplasia (PIN) 
lesions were present. Other studies began dietary interventions prior to initiation of 
carcinogenesis or puberty
8–12
. The initiation of a TP diet in TRAMP mice after puberty when 
prostate-specific pathological changes occur has not been previously investigated. We 
hypothesized that a standard TP diet intervention directly after puberty would reduce PCa 
incidence in the TRAMP model.  
MATERIALS AND METHODS 
Animal Methods. The University of Illinois Laboratory Animal Care Advisory 
Committee approved all animal procedures. Female and male heterozygous TRAMP (C57BL/6) 
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mice from our colony were bred with FVB/NJ mice (Jackson Labs, CA) to obtain 
(TRAMPxFVB/NJ)F1 offspring for the study. Mice were genotyped via PCR-based DNA 
(Sigma-Aldrich, Saint Louis, MO) screening using established methods
10
. Offspring were 
weaned at 3 weeks of age, individually housed in shoebox cages under controlled conditions (12 
h light/dark cycle, 22 ºC, 60% humidity) and acclimated to a pelleted, semi-purified AIN-93G 
diet for 4 weeks. At seven weeks of age, mice were acclimated to consume powdered AIN-93G 
control diet and at 8 weeks of age, mice were randomized to consume powdered study diets of 
AIN-93G control or AIN-93G + 10% TP until sacrifice. Sacrifice time points were randomized 
at weaning and mice were assigned to a sacrifice age of 12 weeks (n=29 control and n=30 TP), 
16 weeks (n=30 control or n=30 TP), or 20 weeks of age (n=29 control and n=30 TP). Non-
transgenic littermates were included in the study to confirm the effects of the transgene and 
sacrificed at 12 (n=5/diet), 16 (n=5/diet), and 20 weeks of age (n=14/diet). An additional cohort 
of mice (n=9) were fed control AIN-93G pellets and sacrificed at 8 weeks of age to confirm the 
stage of carcinogenesis we initiated our dietary intervention.  
At 12, 16, and 20 weeks of age, mice were asphyxiated by CO2 and blood was collected 
via cardiac puncture. Serum was separated following centrifugation, aliquotted, frozen, and 
stored for analyses. The prostate was micro-dissected into individual lobes (anterior, ventral, and 
dorso-lateral). One half of each prostate lobe was fixed overnight in 10% phosphate-buffered 
formalin and then transferred to 70% ethanol for histological evaluation. All animals were 
thoroughly examined for gross metastases by trained research staff during the necropsy. A 
section of liver, lungs, and lymph nodes were fixed in 10% phosphate-buffered formalin and 
transferred to 70% ethanol after 24 hours for evaluation of micro-metastases. Liver, testes, 
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seminal vesicles, spleen, gonadal adipose, and one half of each prostate lobe were flash frozen in 
liquid nitrogen and stored at -80 ºC.   
Diet Formulation. Diets were balanced for protein, carbohydrates, fat, energy, and fiber 
and stored at 4 ºC in the dark and have been previously used successfully in our lab
8–10,13
. 
Carotenoid profiles of the diets were measured by high performance liquid chromatography and 
photodiode array (HPLC-PDA) Composition of experimental diets is shown in Table 3.1.  
Diet and Tissue Carotenoid Analyses. Diet and tissue carotenoid analyses were 
performed using previously-published techniques described by our lab
10,14,15
. Briefly, 5 mL of 
ethanol solution containing 0.01% BHT was added to tissue or 25 mg diet, 0.6 g gonadal 
adipose, or 0.1 g of liver. Anterior prostates were pooled within groups to facilitate HPLC 
detection of carotenoids. Both testes from the same animal were extracted as one replicate and 
300 μL of serum was used for analyses. Tissue was minced thoroughly and diet was 
homogenized for 75 s in ethanol/BHT before addition of 1 mL saturated potassium hydroxide. 
Diet and tissues were saponified for 30 minutes at 60°C. Samples were extracted 3 times with 6 
mL hexane, dried in a Speedvac (model AS160; Savant, Farmingdale, NY) evaporator, flushed 
with argon, and stored at −20 °C for ≤ 48 h before reverse-phase HPLC-PDA analysis as 
previously described
15. Analytical standards of lycopene, phytoene, phytofluene, and β-carotene 
were used for quantification. Samples were analyzed using HPLC-PDA (Waters, Milford, MA). 
A C30 reversed phase column (4.6 x 150 mm, 3 μm, YMC, Wilmington, NC) cooled to 18 °C 
was used with methyl-tert butyl ether, methanol, and 1.5% (w/v) aqueous ammonium acetate 
mobile phases to separate phytoene, phytofluene, lycopene, and β-carotene. Specific mobile 
phase composition and gradient elution method were used as described previously
15
. Carotenoids 
were identified and quantified via UV spectra, retention times and standard comparison. 
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Lycopene (Sigma-Aldrich, Saint Louis, MO), phytoene, phytofluene, and ζ-carotene standards 
were purchased (Carotenature, Ostermundigen, Switzerland). β-carotene was extracted from 15% 
beadlets (DSM, Heerlen, Netherlands). Samples were analyzed within 48 hours of extraction. 
Samples were kept at 4 °C on an autosampler cooling tray and handled under yellow light to 
reduce carotenoid degradation.  
Histopathology. One half of each lobe of the prostate (anterior, ventral, and dorso-
lateral) was fixed in 10% formalin overnight and transferred to 70% ethanol. Cassettes were 
paraffin embedded, cut and stained with hematoxylin and eosin (H&E) before examination. A 
blinded and trained pathologist evaluated all of the lobes of the prostate and assigned a score for 
the most severe and most common lesion for each lobe according to a previously published 
grading scheme
16
.  
Serum Vascular Endothelial Growth Factor (VEGF). Serum VEGF was measured 
using an ELISA kit (Abcam, San Francisco, CA) in mice at 12, 16 and 20 weeks of age. 
Real Time Quantitative PCR. RNA was extracted from dorso-lateral prostate lobes 
using the RNeasy Mini Kit (Qiagen, Valencia, CA) and on-column DNase treated with an 
RNase-free DNase kit (Qiagen, Valencia, CA). RNA was reverse transcribed into complimentary 
DNA (cDNA) using the High-Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems, 
Foster City, CA). mRNA expression of selected genes was measured via real-time PCR using 
SYBR Green Master Mix (Applied Biosystems, Foster City, CA). Reactions were monitored by 
an ABI Prism 7900HT. Prostatic levels of VEGF were determined using RT PCR validated 
primers (SA Biosciences, Valencia, CA). Prostatic levels of HSD17β2, HSD17β3, and 5-α 
reductase I were determined using RT PCR validated primers (Bio-Rad, Hercules, CA).  RPL-19 
was used as the housekeeping gene (SA Biosciences, Valencia, CA). Primer pairs were designed 
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for androgen receptor forward-5’-TCTTTCAAGGGAGGTTACGC-3’ and reverse-5’-
AGGACGGGATCTCAAGTGTC-3’, CYP17A1 forward-5’- TAGGCTTCAGTCGAACACCG-
3’ and reverse-5’- TCCTTCGGGATGGCAAACTC-3’, β-microseminoprotein (msmb) forward-
5’-GTCAATCACCTGCTGTACCAAC -3’ and reverse-5’-CTGGGTTCTTCCGATCCAC-3’, 5-
α reductase II forward-5’-AAAGCCACTGCCTTCTGCAT-3’ and reverse-5’-
AAAGCCACTGCCTTCTGCAT-3’, and RPL-19 forward-5’-AAATCGCCAATGCCAACTC-
3’ and reverse-5’-ACCCTTCCTCTTCCCTATGC-3’ (IDT, Coralville, IA).  
Immunohistochemistry. Immunohistochemistry for proliferating cell nuclear antigen 
(PCNA) and cleaved caspase-3 (CC3) were performed on paraffin-embedded (4 µm) fixed 
sections of the dorso-lateral prostate lobe according to a previously published protocols
17,18
. 
Briefly, slides were placed in a decloaking chamber and treated in a citrate buffer (pH 6.0) for 30 
seconds at 125 ºC and 10 seconds at 90 ºC for antigen retrieval. In a BioGenex i6000 Automated 
Staining System, (BioGenex, San Ramon, CA), endogenous peroxide was quenched with a 3% 
H2O2 solution for 15 minutes, slides were blocked with Power Block
TM
 (BioGenex) for 10 
minutes, avidin blocked for 15 minutes, and then incubated with rabbit ant-proliferating cell 
nuclear antigen (PCNA) antibody (Abcam, Cambridge, MA) or rabbit anti-cleaved caspase-3 
(Cell Signaling, Danvers, MA) for 30 minutes and visualized using a SuperSensitive
TM
 Link-
Label IHC Detection System (BioGenex). Slides were stained with DAB and counterstained with 
hematoxylin. Mouse small intestinal tissue was used as the positive control for PCNA and mouse 
thymus tissue was used as the positive control for cleaved caspase-3. Negative controls were 
generated by omitting the primary antibody. Stained slides were scanned with a NanoZoomer 
2.0-HT digital slide scanner (Hamamatsu, Bridgewater, NJ) with Olympus Uplansapo 20X 
objective at 40X digital zoom, resulting in 0.23 µm resolution. Images were captured with NDP 
70 
 
view software (Hamamatsu). One image from the dorso-lateral lobe was blindly quantified and 
the proliferative index (PI) percentage (PCNA positive-stained nuclei/ total nuclei counted x 
100) and apoptotic index (AI) percentage (number of activated caspase-3 cells/ total nuclei 
counted x 100) calculated. These indices were established by counting at least 1000 cells from 
each image.  
Ultrasound Imaging. TRAMP mice were imaged at 10, 12, 16, 18, and 20 weeks of age. 
Mice were anesthetized prior to ultrasound imaging using 2% isofluorane, abdominal fur was 
trimmed, and mice were placed on a heated stage for imaging. 2-dimensional (2-D), 3-
dimensional (3-D), and Doppler ultrasound images were acquired by a trained ultrasonographer 
using the VisualSonics Vevo 2100 high frequency imaging system (VisualSonics, Toronto, 
Canada). 3-D images were constructed from 2-D images taken at special intervals using the 
Vevo 2100 software. Volume was calculated from the constructed 3-D image by manual tracing. 
Each prostate was traced three times and the volumes were averaged to minimize tracing error. 
Serum Testosterone. Serum testosterone was extracted from 150 µL of serum using di-
ethyl ether. After the ether evaporated, a hexane/methanol extraction was used to extract the 
testosterone from other serum lipids for analyses. Serum testosterone was evaluated using the 
Coat-A-Count Total Testosterone Radioimmunoassay (Siemens TKTT2, Los Angeles, CA). 
Statistical Analyses. Data are shown as means ± SEM. Carotenoid analyses, serum 
VEGF, serum testosterone, and proliferation and apoptosis indexes were compared among 
treatments by one-way analysis of variance (ANOVA) followed by post-hoc Tukey-Kramers 
studentized range test with α=0.05 when the assumptions of ANOVA were met; otherwise the 
Wilcoxon and Kruskal-Wallis non-parametric test was used. AR, HSD17β2, HSD17β3, 5α-
reductase I, 5α-reductase II, VEGF, and CYP17A1 were first logarithmically transformed to 
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meet the assumptions of ANOVA. Msmb PCR data was not transformed. All of the mRNA 
expression data was analyzed using 2-tailed ANOVA followed by post-hoc Tukey-Kramers 
studentized range test with α=0.05. Ultrasound volumes were analyzed using ANOVA with 
repeated measures and compared using Tukey-Kramers studentized range test. Additionally, 
linear regression was performed using the REG procedure in SAS. Fisher’s exact test was used to 
compare histopathology scores between the TP group and the control group and each age was 
analyzed separately. Differences in overall cancer incidence, tumor incidence, and metastases 
incidence were analyzed using Fisher’s exact test. All statistical analyses were conducted with 
SAS (version 9.2; SAS Institute, Cary, NC, USA).  
RESULTS  
Body Weight and Food Intake. All diets were readily consumed and there were no 
significant differences in food intake between diets or between groups (p<0.05). Final body 
weights were significantly higher in TP-fed (p=0.02) than control-fed mice only at 16 weeks of 
age. All other beginning and final body weights and intakes were not statistically different 
between groups (Table 3.2). Organ weights are listed as a percent of body weight in Table 3.3. 
In TRAMP mice at 16 weeks of age, control-fed mice had significantly increased urogenital tract 
(UGT) weight compared to TP-fed mice (p=0.005). Furthermore, TP-fed mice had significantly 
increased gonadal adipose (p=0.002) compared to control-fed mice. Lastly, TP-fed wild-type 
mice at 16 weeks of age had increased liver weight (p=0.005) as a percent of body weight 
compared to control wild-type mice.  
Diet Carotenoid Profiles. Diets were prepared in five batches over the duration of the 
study. There was no difference between carotenoid content between each batch. The most 
abundant carotenoid in the diet used in this study was phytoene, a colorless precursor to lycopene 
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(Figure 3.1). Lycopene was only present at 23 µmol/Kg (12.3 ppm) diet, which is substantially 
lower than previous TP studies conducted in our lab
9,10,13
. The TP sourced for the current study 
was provided by Futureceuticals (Momence, IL) and is a standard drum-dried TP with the seeds 
and skins included. This lot of TP had considerably lower levels of tomato carotenoids compared 
to the 286 ppm TP used by Zuniga et al. and other studies carried out in our lab
10,19,20
.  
Tissue Carotenoid Accumulation. Liver, gonadal adipose, testes, serum, and prostatic 
carotenoid accumulation is shown in Table 3.4. Mirroring the diet (see Figure 3.1), hepatic 
lycopene was lower than hepatic phytoene at all ages. Additionally, total gonadal adipose 
carotenoid accumulation was significantly increased in mice at 20 weeks of age when compared 
to mice at 12 weeks of age (p=0.02). Lycopene deposition increased significantly in gonadal 
adipose (p=0.01) in mice at 20 weeks of age compared to mice at 12 weeks of age. As previously 
observed in prostate and other androgen-sensitive tissues, phytoene was absent from the prostate 
and testes
15,19
.  
Histopathology. We confirmed through histopathological evaluation of 8 week-old 
TRAMP mice that they had moderate- and high-grade PIN lesions when our dietary intervention 
was initiated. This confirms that our dietary intervention was initiated when the prostate was in a 
precancerous stage and was no longer considered normal tissue. There were no differences due 
to diet in the most severe or most common lesion in either the anterior, ventral, and dorso-lateral 
lobes at 12, 16 or 20 weeks of age. Furthermore, there were no significant differences when all 
lobes were combined for the most severe and most common lesion overall at 12, 16, or 20 weeks 
of age. Table 3.5 shows the distribution of scores between diets at each age. When examined by 
cancer stage within each age, there were no differences in the 12 or 20 week old animals. 
However, mice at 16 weeks of age consuming the TP diet had significantly increased high-grade 
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PIN (HGP) lesions (p=0.014) and significantly decreased incidence of poorly differentiated (PD) 
lesions (p=0.024) than mice on the control diet. Although total cancer incidence between tomato 
and control diets at 16 weeks of age was not different, this may suggest that the TP diet modestly 
delayed the progression from HGP to PD lesions at this age. The diet effect was not observed in 
mice at 20 weeks of age suggesting that the transition from precancerous to cancerous lesions 
might be short-lived or overwhelmed by the aggressive growth of early developing PD tumors.   
The incidences of gross prostate tumors and gross metastases to pelvic lymph nodes were 
examined at necropsy and the results are represented in Table 3.6. There were no gross tumors 
or metastases observed in 12 week old TRAMP mice. However, in 16 week old mice, there was 
a statistically significant increase (p=0.05) in the incidence of gross prostate tumors in control-
fed mice compared to the TP-fed mice. Similarly to the prostate histopathological data, there was 
no difference in the incidence of gross prostate tumors and gross pelvic lymph node metastases 
in mice at 20 weeks of age.  
Serum VEGF. Serum VEGF was significantly increased (p=0.001) in mice at 20 weeks 
of age compared to mice at 12 and 16 weeks of age (Figure 3.2). No significant differences were 
observed between diets at any age (Figure 3.2), but TP-fed mice had numerically less amount of 
VEGF at 12, 16, and 20 weeks of age.  
VEGF-A mRNA Expression. Prostatic expression of VEGF-A is represented in Figure 
3.3. Similar to serum VEGF levels, there was no difference between diets at 16 and 20 weeks of 
age, but TP tended to reduce VEGF-A expression levels at 16 weeks of age, though this was not 
statistically significant. In contrast, there was a trend that prostatic VEGF-A was increased by TP 
at 20 weeks, though non-significantly.  
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Immunohistochemistry. The apoptotic index (AI) of prostates and tumors stained 
positive for CC3 is represented in Figure 3.4. There was no difference in AI between diets or 
between ages. Tumors had significantly increased AI than prostates with HGP (p < 0.0001). The 
proliferation index (PI) is represented in Figure 3.5. There were no differences in PI between 
diets in mice with HGP.  
Serum Testosterone. We measured serum testosterone in TRAMP mice fed either a 10% 
TP containing diet or a control diet at 12, 16, and 20 weeks of age (Table A.1). At all ages, the 
TP diet numerically increased levels of serum testosterone. Serum testosterone was significantly 
increased in mice fed the TP diet at 16 (p=0.05) and 20 weeks of age (p=0.02) when compared to 
the control diet. Interestingly, serum testosterone was numerically, but not significantly, 
decreased in mice with tumors than in mice with HGP. (Appendix A). 
Androgen Receptor mRNA Expression. In the current study, TP-fed mice had 
significantly (p=0.01) increased expression of AR at 20 weeks of age compared to control fed 
mice (Figure A.2). Furthermore, tumoral expression of AR was significantly lower than in mice 
with HGP (p=0.001), though no significant differences due to diet were detected (Figure A.3, 
Appendix A). 
5-alpha reductase I and II Expression. Prostatic mRNA expression of 5α-reductase I 
and II were not statistically different between control and TP groups at 12, 16, or 20 weeks of 
age. However, there was a significant decrease in mRNA expression of 5α-reductase I (p=0.02) 
and II (p<0.001) in mice with tumors compared to mice with PIN (Figure A.4, Appendix A). 
CYP17A1 mRNA Expression. There was no difference in CYP17A1 expression 
between diet groups at 12, 16, or 20 weeks of age. There was a significant increase in CYP17A1 
expression in tumors than in HGP (p < 0.001) (Figure A.5, Appendix A). 
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HSD17β2 and HSD17β3 mRNA Expression. mRNA expression of HSD17β2 and 
HSD17β3 was not different between diets at 12, 16, and 20 weeks of age. In mice with tumors, 
HSD17β3 expression was significantly decreased (p=0.004) compared to mice with HGP 
(Figure A.6, Appendix A). There was no significant pathology effect of HSD17β2.  
β-microseminoprotein (msmb) mRNA Expression. Prostatic msmb signaling was 
significantly decreased (p<0.001) in mice with tumors compared to mice with PIN (Figure A.7, 
Appendix A). There was no effect of diet at 12, 16, or 20 weeks of age. 
Ultrasound Imaging. Longitudinal 3-D images of the prostate were taken every two 
weeks. 3-D ultrasound volumes of tumors were highly correlated with tumor volume and mass at 
necropsy. 3-D calculated volume at 20 weeks of age was correlated at 0.98 with gross tumor 
mass (Figure A.8) and 0.98 with gross tumor volume as measured by calipers (Figure A.9). In 
the current study, there was no difference in the onset or rate of growth of tumors between TP 
(n=5) and control-fed (n=6) mice. As noted before, not all TRAMP mice who underwent 
ultrasound imaging developed a prostate tumor, therefore we statistically analyzed mice with 
tumors separately from mice without tumors. Longitudinal volumes of mice with tumors were 
not different between groups (Figure A.10, Appendix A). Volumes of mice without tumors 
were not significantly different between groups (Figure A.11, Appendix A). 
DISCUSSION 
There are a number of rodent studies examining the effect of lifelong (post-weaning) TP 
consumption on PCa. Previously, we and others observed a reduction in PCa by including a 
high-lycopene containing 10% TP in the diets of TRAMP mice
10,20
. In the current study, we 
hypothesized that a 10% standard TP diet initiated at 8 weeks of age when preneoplastic 
prostatic lesions were present, would reduce the incidence of PCa compared to the control diet at 
76 
 
12, 16, and 20 weeks of age. However, total cancer incidence, as defined as having at least one 
of the following lesions: well differentiated (WD), moderately differentiated (MD), or PD, was 
not statistically impacted by diet at either 12, 16, or 20 weeks of age.  
Despite the lack of a significant decrease in overall cancer incidence, TP may have been 
effective in delaying the progression from precancerous lesions to cancerous lesions in mice at 
16 weeks of age. TP-fed mice at 16 weeks of age had a significantly increased incidence of HGP 
and a significantly decreased incidence of PD lesions compared to control-fed mice (p=0.01).  
This suggests that TP may have delayed the progression from precancerous HGP lesions to 
invasive PD lesions at this single time point. Additionally, 16 week old control-fed mice had 
increased urogenital-tract weight (p=0.005) and an increased incidence of gross tumors at 
necropsy than TP-fed mice. This may suggest that control-fed mice had more advanced tumors 
that were larger at necropsy and may have had a more invasive potential than TP-fed mice. 
However, any differences in pathologies were lost by 20 weeks of age. 
Angiogenesis is a process by which new vasculature can be formed. Men with PCa have 
been shown to have increased serum levels and expression of VEGF
11,21
. We measured serum 
levels of VEGF at 12, 16, and 20 weeks of age and prostatic mRNA expression of VEGF-A in 
mice at 16 and 20 weeks of age to determine if a 10% TP diet intervention reduced VEGF-A and 
by inferences, angiogenesis, compared to the control mice. While mice at 20 weeks of age had 
significantly increased levels of serum VEGF, there were no significant differences between 
diets at any age. However, there was a slight trend that serum VEGF was numerically reduced by 
TP at 12, 16, and 20 weeks of age. Prostatic mRNA expression of VEGF followed a similar trend 
as serum at 16 weeks of age, in that it appeared there was a numerical reduction of VEGF by the 
TP diet, however, that was not the case at 20 weeks of age.  
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Apoptosis and proliferation have been shown to be impacted by TP and lycopene in cell 
and animal models of PCa
5,9,10,22,23
. However, in the current study there were no significant 
differences in the AI and PI between dietary groups at 12, 16, and 20 weeks of age. There was a 
trend toward reduced apoptosis in the TP group at 16 weeks of age, though the change was non-
significant. There were no diet effects on prostatic gene expression. However, there were 
significant differences between expression in prostates with HGP and in prostate tumors. Tumors 
had significantly reduced expression of AR suggesting that they relied on a different source of 
androgens for growth and development and possibly suggesting a castration-resistant PCa 
phenotype. CYP17A1 and 5-alpha reductase II expression in tumors also indicated a shift 
towards a castration-resistant PCa phenotype. However, tumors had significantly lower 
expression of HSD17β3 which is typically over-expressed in advanced PCa.  
While we observed a modest effect on cancer incidence by TP at 16 weeks of age, we 
suggest that there are two variables that may have contributed to the lack of a robust effect in 
overall cancer incidence: 1) the carotenoid content of the TP and 2) the timing of our 
intervention.  
 In previous studies using rodent models of PCa, TP and/or lycopene have been observed 
to drastically reduce PCa incidence
8–10,24
. However, the current study resulted in a modest 
reduction. A commercially-available drum-dried TP including the skins and seeds was analyzed 
and used to formulate our intervention diet. The TP used was a standard TP containing more than 
30-fold less lycopene than the TP Zuniga et al. used
13
. There are several factors that can 
influence tomato carotenoid content, including geographical location grown and growing season, 
cultivation methods, weather conditions, use of nitrogenous fertilizers, and the tomato 
variety
25,26
. 
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The lower lycopene content of the TP used in the current study could well be responsible 
for the modest results observed. Previously, TP diets used in TRAMP studies provided lycopene 
ranging from 132-286 ppm, and were effective at reducing PCa incidence
10,11
. Zuniga et al. 
observed a 39% decrease in cancer incidence in mice consuming 286 ppm lycopene from a 10% 
TP diet
10
. In another study, increased overall survival of TRAMP mice was observed in mice 
consuming 132 ppm lycopene from a 10% TP diet
24
. However, Konijeti et al., determined that 28 
ppm lycopene from a tomato paste diet was ineffective in reducing PCa incidence in the TRAMP 
model
27
. Interestingly, 100 ppm of lycopene from beadlets was effective in that study
27
 The 
current study provided only 12.3 ppm lycopene from the 10% TP diet. Collectively, the results of 
these TRAMP studies suggest a possible threshold level of lycopene necessary to affect cancer 
incidence in this aggressive transgenic model of PCa. It is interesting to note, however, that 
levels of carotenoids found in the gonadal adipose, serum, and prostate were similar to a 
previous study in our laboratory, whereas, hepatic lycopene at 20 weeks of age was four-fold 
lower than previously observed at 18 weeks of age (Figure 3.6/Table 3.7)
10
.  
An alternative hypothesis for the findings is related to the timing of the dietary 
intervention. The TP intervention was designed to mimic the dietary changes a man newly 
diagnosed with PCa might adopt. In our study, TP diets were consumed post-puberty when 
prostates had already progressed to low- and moderate-grade PIN. It is possible that the dietary 
intervention was too late to delay or impact the transgenic cancer process in this aggressive 
model of PCa. Research has shown that by 10 weeks of age, there is a genotype effect in 
TRAMP mice that results in an up-regulation of genes involved in cell growth and cell-cycle 
regulation
12
. A 10% TP diet initiated at 4 weeks of age in TRAMP mice was also shown to alter 
androgen metabolism and signaling at 10 weeks of age
12
. This may suggest that there is a critical 
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period of time where dietary studies of TP and lycopene may be effective in this model. Other 
studies utilizing TP and/or lycopene in the TRAMP model began dietary treatments at 3 and 4 
weeks of age, after weaning and before puberty, and observed significant effects in cancer 
outcomes by diet
10,11
. Our study suggests that beginning a dietary intervention after puberty 
results in a less robust effect in cancer incidence in this model. Additionally, while carotenoid 
accumulation in tissues was similar between studies at 16 and 20 weeks of age, tissues at 12 
weeks of age had lower amounts of carotenoid concentrations (Table 3.4), indicating that four 
weeks of TP feeding may not be enough to significantly alter genes involved in androgen 
metabolism and synthesis to impact this critical time in cancer development. Epidemiological 
evidence suggests that long-term or early dietary lycopene intake is likely more effective for PCa 
prevention than recent intake
30
. Together, this study further emphasizes the importance of 
lifelong consumption of tomatoes and/or lycopene-containing foods to potentially reduce the risk 
of PCa.  
According to the USDA National Nutrient Database values for lycopene in tomato 
products, the current study diet provided the amount of lycopene found in 1.4 cups of raw cherry 
tomatoes; an amount realistically consumable by an adult. Although total cancer incidence was 
not different between diets, TP may have delayed the progression of preneoplastic PCa to 
invasive PCa at 16 weeks of age. There may be a critical period of lycopene exposure necessary 
to confer protection in PCa and future studies should continue to determine if early lycopene 
exposure is key in delaying the development of PCa. It is clear that tomatoes contain components 
that alter androgen signaling in the prostate, however, the minimum amount required to observe 
an effect appears to vary between animal models. Future studies examining TP should focus on 
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the effect of exposure timing and lycopene content of the diet to determine the effectiveness of 
this dietary approach for reducing the risk of PCa.  
ABBREVIATIONS USED 
BHT, butylated hydroxytoluene; HPLC-PDA, high performance liquid chromatography-
photodiode array. 
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FIGURES AND TABLES 
Table 3.1. Composition of Experimental Diets 
g/100g total diet 
  AIN-93G Control AIN-93G + 10% TP 
a
 
Cornstarch 39.7 35.2 
Casein 20 18.5 
Maltodextrin 13.2 11.8 
Sucrose 10 10 
Fiber 
b
 5 3.3 
Mineral Mix 
c
 3.5 3.5 
Vitamin Mix 
d
 1 1 
L-Cystine 0.3 0.3 
Choline Bitrate 0.3 0.3 
Soybean Oil 7 6.5 
Tomato Powder 
e
 - 10 
a
 10% TP contains 23.8 μmol of lycopene, 30.1 μmol of phytoene, 16.7 μmol of phytofluene, and 
2.6 μmol of β-carotene per Kg of diet.  
b
 Non-nutritive cellulose 
c 
AIN-93G-MX formation 
d
 AIN-93G-VX formation 
e
 FutureCeuticals Drum Dried Tomato Powder-20 
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Table 3.2. TRAMP and Wild-Type Body Weights and Food Intake 
 
TRAMP Wild Type 
 
 
AIN-93G 
Control 
10% Tomato 
Powder 
AIN-93G 
Control 
10% Tomato 
Powder 
 12 weeks of age 
Beginning Body 
Weight 
19.3 ± 0.6 21 ± 0.6 21.4 ± 0.7 18 ± 1.8 
 Ending Body Weight 32 ± 3.5 33 ± 3.8 33.9 ± 5.5 32 ± 4.1 
 Feed Intake (g/day) 6 ± 0.2 6.2 ± 0.06 6.3 ± 0.07 6.3 ± 0.09 
 n 29 30 5 5  
16 weeks of age 
Beginning Body 
Weight 
19.2 ± 0.5 19.5 ± 0.4 19.6 ± 0.5 20 ± 0.9 
 Ending Body Weight 36.4 ± 4.6 
a
 39 ± 3.6 
b
 39.7 ± 4.1 43 ± 2.9 
 Feed Intake (g/day) 5.9 ± 0.1 5.7 ± 0.1 5.7 ± 0.3 5.2 ± 0.5 
 n 30 30 5 5  
20 weeks of age 
Beginning Body 
Weight 
19.8 ± 0.6 18 ± 0.5 20.4 ± 1 18.7 ± 0.6 
 Ending Body 
Weight 
39.5 ± 5.7 38.9 ± 4.5 36.1 ± 6 40 ± 4 
 Feed Intake (g/day) 5.5 ± 0.2 5.3 ± 0.1 5.7 ± 0.2 5.1 ± 0.4 
 n 29 30 14 14  
Values are the mean ± SEM.  
Different superscript letters within a row and within the same genotype indicate significant 
differences between diets (p<0.05).
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Table 3.3. TRAMP and Wild-Type Organ Weights as a Percent of Final Body Weight 
TRAMP 
 
UGT Liver 
Seminal 
Vesicles 
Testes 
Gonadal 
Adipose 
Lungs Spleen 
Ventral 
Prostate 
Anterior 
Prostate 
Dorso-
lateral 
Prostate 
12 weeks Control 1.6 ± 0.3 4.1 ± 0.8 1.1 ± 0.2 0.7 ± 0.1 3.6 ± 0.7 0.8 ± 0.2 0.3 ± 0.05 0.067 ± 0.01 0.2 ± 0.03 0.05 ± 0.01 
 
Tomato 1.7 ± 0.32 4.2 ± 0.8 1.2 ± 0.2 0.7 ± 0.1 3.8 ± 0.7 0.8 ± 0.2 0.3 ± 0.05 0.06 ± 0.01 0.2 ± 0.03 0.05 ± 0.01 
16 weeks Control 3.7 ± 0.7 3.9 ± 0.7 1.2 ± 0.2 0.6 ± 0.1 4.1 ± 0.8 0.7 ± 0.1 0.2 ± 0.06 0.09 ± 0.02 0.2 ± 0.04 0.08 ± 0.02 
 
Tomato 2.1 ± 0.4
# 3.9 ± 0.8 1.2 ± 0.2 0.6 ± 0.1 4.9 ± 0.9# 0.7 ± 0.1 0.2 ± 0.05 0.08 ± 0.02 0.2 ± 0.03 0.07 ± 0.01 
20 weeks Control 7.5 ± 0.71 4 ± 0.7 1.4 ± 0.2 0.6 ± 0.1 3.6 ± 0.8 0.6 ± 0.1 0.2 ± 0.06 0.1 ± 0.02 0.2 ± 0.04 0.1 ± 0.02 
 
Tomato 7.5 ± 1.4 3.9 ± 0.7 1.6 ± 0.3 0.6 ± 0.1 3.6 ± 0.7 0.7 ± 0.1 0.3 ± 0.07 0.1 ± 0.02 0.2 ± 0.04 0.1 ± 0.03 
            
Wild Type UGT Liver 
Seminal 
Vesicles 
Testes 
Gonadal 
Adipose 
Lungs Spleen 
Ventral 
Prostate 
Anterior 
Prostate 
Dorso-
lateral 
Prostate 
12 weeks Control 1.6 ± 0.9 4.3 ± 2.1 1 ± 0.5 0.7 ± 0.4 5 ± 2.5 0.3 ± 0.1 0.3 ± 0.1 0.05 ± 0.02 0.02 ± 0.08 0.03 ± 0.02 
 
Tomato 1.3 ± 0.7 4.6 ± 2.6 0.8 ± 0.5 0.7 ± 0.4 4.1 ± 2.4 0.3 ± 0.1 0.3 ± 0.1 0.03 ± 0.02 0.1 ± 0.08 0.02 ± 0.01 
16 weeks Control 1.1 ± 0.5 3.9 ± 1.9 0.7 ± 0.4 0.5 ± 0.3 4.6 ± 2.3 0.2 ± 0.1 0.2 ± 0.1 0.03 ± 0.02 0.1 ± 0.06 0.02 ± 0.01 
 
Tomato 1.1 ± 0.6 4.3 ± 2.1
# 1 ± 0.5 0.5 ± 0.2 5 ± 2.5 0.2 ± 0.1 0.2 ± 0.1 0.03 ± 0.02 0.1 ± 0.06 0.02 ± 0.01 
20 weeks Control 1.3 ± 0.4 4.1 ± 1.2 0.9 ± 0.3 0.7 ± 0.2 3.7 ± 1.1 0.2 ± 0.01 0.2 ± 0.01 0.05 ± 0.01 0.1 ± 0.04 
0.03 ± 
0.009 
 
Tomato 1.3 ± 0.4 4 ± 1.2 0.9 ± 0.3 0.6 ± 0.2 4.4 ± 1.3 0.2 ± 0.09 0.2 ± 0.09 0.04 ± 0.01 0.1 ± 0.04 0.03 ± 0.01 
Values represent means ± SEM.  
# indicates a significant difference (p<0.05) from the control group within a tissue and within an age. 
 
84 
 
Figure 3.1. Percentage of Carotenoids in a 10% TP Diet 
 
 
  
42% 
23% 
32% 
4% 
Percentage of Carotenoids in 10% Tomato Powder Diet 
Phytoene
Phytofluene
Lycopene
Beta-carotene
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Table 3.4. Serum and Tissue Carotenoid Concentration in 10% TP-fed TRAMP 
Serum (umol/L) (n=5) 
Carotenoid 12 weeks 16 weeks 20 weeks 
Phytoene ND ND ND 
Phytofluene ND ND ND 
Lycopene 0.47 ± 0.07 0.81 ± 0.18 0.66 ± 0.15 
β-carotene ND ND ND 
Total Carotenoids 0.47 ± 0.07 0.81 ± 0.18 0.66 ± 0.15 
Liver (nmol/g) (n=12) 
Phytoene 2.8 ± 0.5 3.1 ± 0.2 3.2 ± 0.8 
Phytofluene 2.1 ± 0.5 2.6 ± 0.8 1.3 ± 0.4 
Lycopene 1.4 ± 0.2 2.4 ± 0.5 1.9 ± 0.3 
β-carotene ND ND ND 
Total Carotenoids 6.3 ± 0.9 8 ± 1.2 6.4 ± 1.1 
Gonadal Adipose (nmol/g) (n=10) 
Phytoene 0.05 ± 0.02 0.07 ± 0.02 0.07 ± 0.03 
Phytofluene 0.02 ± 0.003 0.03 ± 0.005 0.03 ± 0.01 
Lycopene 0.1 ± 0.0
a
 0.3 ± 0.05 
ab
 0.5 ± 0.1 
b
 
β-carotene ND ND ND 
Total Carotenoids 0.2 ± 0.03
a
 0.4 ± 0.06 
ab
 0.6 ± 0.2 
b
 
Testes (nmol/g) (n=10) 
Phytoene ND ND ND 
Phytofluene 0.04 ± 0.006 0.08 ± 0.01 0.05 ± 0.005 
Lycopene 0.3 ± 0.05 0.4 ± 0.07 0.4 ± 0.03 
β-carotene ND ND 0.1 ± 0.01 
Total Carotenoids 0.03 ± 0.04 0.4 ± 0.06 0.4 ± 0.07 
Anterior Prostate (nmol/g) (n=6-8) 
Phytoene ND ND ND 
Phytofluene 0.4 ± 0.2 0.3 ± 0.1 0.3 ± 0.1 
Lycopene 0.4 ± 0.2 0.4 ± 0.1 0.4 ± 0.1 
β-carotene ND ND ND 
Total Carotenoids 0.6 ± 0.2 0.5 ± 0.2 0.7 ± 0.2 
Values are the mean ± SEM.  
Different superscript letters within a row indicate significant differences between ages (p<0.05) 
ND = carotenoid levels below detection limit of detection (0.02 nmol/g phytoene, 0.5 nmol/g 
phytofluene, and 0.5 nmol/g β-carotene). 
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Table 3.5. TRAMP Histopathology Results as a Percentage of Total Prostatic Lesions by Age 
and Diet 
TRAMP 
   
PIN 
 
Adenocarcinoma 
Prostate 
Cancer 
(WD-
PD) 
    
Diet n 
Age 
(weeks) NP LGP MGP HGP PLL WD MD PD 
 
Control 28 12 3.6% 0% 0% 89.3% 3.6% 0% 3.6% 0% 3.6% 
Tomato 30 12 6.7% 3.3% 3.3% 80% 0% 0% 6.7% 0% 6.7% 
Control 30 16 6.7% 0% 10% 43.3% 6.7% 6.7% 10% 16.7% 33.3% 
Tomato 30 16 0% 0% 3.3% 76.7%# 3.3% 6.7% 10% 0%# 16.7% 
Control 29 20 3.4% 0% 3.4% 31% 10.3% 3.4% 27.6% 20.7% 51.7% 
Tomato 30 20 3.3% 0% 3.3% 40% 6.7% 13.3% 10% 26.7% 50% 
NP = Normal Prostate, LG = low grade PIN, MG = moderate grade PIN, HG = high-grade PIN, 
PLL = phyllode-like lesions, WD = well differentiated, MD = moderately differentiated, PD = 
poorly differentiated.  
Results are the incidence of each stage of pathology and overall incidence (sum of WD-PD) 
within dietary groups.  
# Indicates a significant difference (p<0.05) from the control group at 16 weeks of age.  
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Table 3.6. TRAMP Gross Tumor and Lymph Node Metastases Incidence by Diet and Age 
Weeks of Age n Diet Tumor 
Lymph Node 
Metastases 
12 29 Control 0% 0% 
 
30 Tomato 0% 0% 
16 30 Control 33% 10% 
 
30 Tomato 10% 
#
 0% 
20 29 Control 45% 24% 
 
30 Tomato 37% 20% 
Values represent the percentage of TRAMP mice with gross tumors and gross pelvic lymph node 
metastases by age and diet.  
# Indicates a significant difference (p<0.05) from the control at 16 weeks of age.  
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Figure 3.2. TRAMP Serum VEGF by Age and Diet 
 
Values are the mean ± SEM.  
# Indicates a significant difference (p<0.05).  
 
Figure 3.3. Prostatic mRNA Expression of VEGF-A by Age and Diet 
 
Values are the mean ± SEM.  
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Figure 3.4. Prostatic Apoptosis Index at 16 Weeks of Age 
 
Values are the mean ± SEM.  
 
Figure 3.5. Prostatic Proliferation Index at 16 Weeks of Age 
 
Values are the mean ± SEM.  
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Figure 3.6. Tissue Lycopene Accumulation between Studies 
 
Values are the mean ± SEM.  
Current study tissue carotenoid concentrations were measured at 20 weeks of age. Zuniga et al.
10
 
tissue carotenoid concentrations were measured at 18 weeks of age. 
 
Table 3.7. Tissue Lycopene Accumulation between Studies  
 
Current Study 
 
Zuniga et al.
10
 
Tissue 20 weeks n  18 weeks n 
Serum (µmol/L) 0.66 ± 0.15 5  0.67 ± 0.07 7 
Liver (nmol/g) 1.9 ± 0.3 12  4.56 ± 0.91 7 
Gonadal Adipose 
(nmol/g) 
0.5 ± 0.1 10  0.9  ±  0.19 14 
Testes (nmol/g) 0.4 ± 0.03 10  1.42 ± 0.23 5 
Prostate (nmol/g) 0.4 ± 0.1 6-8  0.25 ± 0.05 5-8 
Values are the mean ± SEM.  
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CHAPTER 4 
Pelleting Diets Impairs TRAMP Prostate Carcinogenesis 1 
ABSTRACT 
Prostate cancer (PCa) is the most commonly diagnosed male cancer in U.S. men. 
Daidzein, the major isoflavone present in soy germ, can be metabolized by the gut microbiota 
into equol. The effects of daidzein and equol on PCa are not well studied. The objective of this 
study was to investigate the effect of feeding 2% soy germ, daidzein, or equol on the progression 
of PCa in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. 3-week old 
male C57BL/6 X FVB TRAMP mice were weaned from our breeding colony and immediately 
acclimated to an AIN-93G control diet for one week. At 4 weeks of age, mice (n=30 per diet 
group) were randomized to one of four pelleted study diets, AIN-93G control, AIN-93G + 2% 
soy germ, AIN-93G + 92 ppm daidzein, or AIN-93G + 88 ppm equol until 18 weeks of age. To 
our surprise, we did not detect any statistical differences in cancer incidence between diets. 
Previously, we observed a 100% cancer incidence in TRAMP mice fed a control diet until 18 
weeks of age, however, the control group in this study only had a 24% incidence in cancer at this 
same age
1
. These findings are likely the result of the physical attributes of the pelleted study 
diets. Mice fed pelleted diets had lower food intake and significantly decreased body weights 
(p<0.001) compared to those fed powdered diets in a previous study
1
. A reduction in food intake 
is known to reduce cancer incidence in a number of cancer models and is likely to have 
contributed to the decrease in expected cancer incidence in the current study. In mice with 
tumors, daidzein and equol diets significantly altered the serum levels of cytokines, IL-1β, IL-10, 
IFN-γ, and TNF-α compared to the control and soy germ groups suggesting that daidzein and 
equol may play a role in moderating tumoral inflammation. In conclusion, we determined that 
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pelleting the diets resulted in significantly decreased food intake and body weights and decreased 
cancer incidence. There was no difference in cancer incidence between diets, but we did see a 
significant effect of daidzein and equol on serum inflammatory cytokines in tumors which may 
suggest a reduction in inflammation in advanced PCa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 Additional tables and figures not included in this chapter are in Appendix B.  
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INTRODUCTION 
Prostate cancer (PCa) is the most common cancer in men and is the second leading cause 
of cancer deaths in men in the U.S
2
. The incidence of PCa varies widely among regions in the 
world with the US, France, Barbados, and Sweden reporting some of the highest incidences and 
countries such as Japan, China, and South Korea reporting some of the lowest incidences
3
. Risk 
factors for PCa include age, genetics, family history, race, smoking, obesity, and diet
4,5
. Dietary 
factors have been widely hypothesized to account for differences in PCa rates between regions of 
the world. Immigration studies have shown a 3 to 5-fold increase in PCa risk in Asian-American 
immigrants compared to their native counterparts
6
. These results suggest that PCa risk is 
relatively low in native Asian countries, but the risk is increased in Asian men living in Western 
countries
6
.  
Over the last 30 years, evidence that a diet rich in soy products may be protective against 
PCa, has been growing. Soy products contain an array of bioactive compounds including 
saponins, lignans, and the isoflavones genistein, daidzein, and glycitein. Intake of isoflavones 
varies geographically. Consumption of isoflavone-rich foods such as tofu, tempeh, and miso is 
common in Asian countries where dietary intakes of isoflavones have been estimated to range 
from 15 mg/day in China to 26-54 mg/day in Japan, while the average intake of isoflavones in 
Western countries is estimated at 3 mg/day
7,8
.  
Our lab recently demonstrated that consumption of a 2% soy germ diet reduced the 
incidence of PCa in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model by 
34% compared to the control diets
1
. Soy germ, the hypocotyl of the soybean, has a radically 
different isoflavone profile than whole soybeans. It contains considerably higher levels of 
daidzein and glycitein and relatively low levels of genistein when compared to whole soybeans. 
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Soy germ is currently utilized in dietary supplements, and food scientists have been investigating 
ways to incorporate it into functional foods for disease prevention
11–14
. Therefore, it would be 
beneficial to determine the anticancer effects of soy germ and its mechanisms of action.  
Genistein, the predominant isoflavone in soy products, has been investigated for its anti-
proliferative, antioxidant, and chemopreventive properties in cell, animal, and human models
9,10
. 
Although genistein has been associated with a protection against several cancers and other 
chronic diseases, there is a need to investigate the effects of other commonly-consumed 
isoflavones, daidzein, glycitein, and their metabolites.  
Epidemiological studies suggest a reduced risk of PCa in men who consume soy 
products
15, and this effect appears to be especially pronounced in men who are “equol 
producers” (> 20 nM serum equol)16. Daidzein can be metabolized by the gut microbiota into the 
weak estrogen-like compound, equol. It is not well understood if equol production is responsible 
for the protective effect observed with soy intake. Equol has been shown to have a higher 
binding affinity for estrogen receptor-β (ERβ) than daidzein17. Equol has also been shown in 
vitro and in vivo to bind 5α-dihydroxytestosterone (DHT), thereby inhibiting its binding to the 
androgen receptor modulating androgen signaling in the prostate
18
. This is significant because 
equol’s ability to be a selective estrogen modulator as well as an androgen antagonist makes it a 
promising target to study for hormonally-driven cancers like PCa.  
In TRAMP mice, we previously demonstrated that prostatic equol was 39 times higher 
than genistein and 3 times higher than daidzein in mice consuming soy germ
1
. The elevated 
concentration of equol in the prostate suggests that equol was a critical contributor to the 
anticarcinogenic effects of soy germ found in the TRAMP model
1
. If the benefits from soy germ 
are primarily attributed to equol production, then an estimated 70-75% of the Western population 
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would not benefit from soy germ consumption as it is estimated that only 25-30% of the 
populations in Western countries are equol “producers” compared to up to 80% of individuals in 
China, Japan, and South Korea
19
.  
Limited in vivo studies have directly examined feeding equol and the incidence of PCa in 
rodents. Due to the previously observed protective effect of soy germ, we designed this study to 
follow-up on the results from Zuniga et al. and compare the effects of soy germ, daidzein, and 
equol in prostate carcinogenesis
1
. We hypothesized that equol was primarily responsible for the 
protective effect of soy germ, and that the soy germ, daidzein, and equol-fed mice would have 
reduced cancer incidence compared to the control group. 
MATERIALS AND METHODS 
Animal Methods. The University of Illinois Laboratory Animal Care Advisory 
Committee approved all animal procedures. Female and male heterozygous TRAMP (C57BL/6) 
mice from our colony were bred with FVB/NJ mice to obtain (TRAMPxFVB/NJ)F1 offspring for 
the study. A minimum of 28 mice per diet group were projected to be needed to reach statistical 
significance by power analysis (α=0.05, β=0.8) for cancer incidence and two extra mice were 
added to each diet group to account for the occasional unforeseen death of study animals. Mice 
were genotyped via PCR-based DNA (Sigma-Aldrich, Saint Louis, MO) screening using 
established methods
1
. Offspring were weaned at 3 weeks of age, individually housed in shoebox 
cages under controlled conditions (12 h light/dark cycle, 22 ºC, 60% humidity) and acclimated to 
a pelleted, modified semi-purified AIN-93G diet for one week. The modified AIN-93G included 
corn oil instead of standard soybean oil as the fat source. At 4 weeks of age, mice were 
randomized to consume one of four experimental diets: AIN-93G control, AIN-93G + 2% soy 
germ, AIN-93G + 82 ppm daidzein, or AIN-93G + 88 ppm equol. The daidzein diet included 92 
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ppm of purified daidzein to match levels found in a 2% soy germ diet. Equol was matched to 
daidzein equivalents found in a 2% soy germ diet with the assumption that 100% of the daidzein 
would be metabolized to equol by the highly efficient microbiota in the mouse
20
. Non-transgenic 
control littermates (n=10 per diet group) were included in the study to confirm the effects of the 
transgene. 
Mice were weighed and individual food intake was measured when fresh food was 
provided weekly. At 18 weeks of age, mice were asphyxiated by CO2 and blood was collected 
via cardiac puncture. Serum was separated following centrifugation, aliquotted, frozen, and 
stored for analyses. The prostate was micro-dissected into individual lobes (anterior, ventral, and 
dorso-lateral). One half of each prostate lobe was fixed overnight in 10% phosphate-buffered 
formalin and then transferred to 70% ethanol for histological evaluation. All animals were 
thoroughly examined for gross metastases by trained research staff during the necropsy. A 
section of liver, lungs, and lymph nodes were fixed in 10% phosphate-buffered formalin and 
transferred to 70% ethanol after 24 hours for evaluation of micro-metastases. Liver, testes, 
spleen, gonadal adipose, and one half of each prostate lobe were flash frozen in liquid nitrogen 
and stored at -80 ºC.   
Diet Formulation and Isoflavone Analysis. Experimental diets were prepared as a 
custom AIN-93G formulation by Harlan Laboratories (Madison, WI). Diets were balanced for 
protein, carbohydrates, fat, energy, and fiber, provided 3.8 Kcal/g, and were stored at 4 ºC in the 
dark. Experimental diet compositions are presented in Table 4.1. Soy germ was analyzed for 
daidzein isoflavone equivalents. Isoflavone content of the final experimental diets was analyzed 
by the National Center for Toxicological Research in Jefferson, AR using HPLC-UV. Briefly, 
500 mg of diet was crushed and ground into a powder and placed in a 15 mL centrifuge tube. 2.5 
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mL of 80% methanol:water (80:20, v/v) was added to each tube. Samples were vortexed and 
then sonicated for 30 minutes. The supernatant was removed following centrifugation and placed 
into a 10 mL volumetric flask. The above methanol:water addition, vortex, sonication, and 
centrifugation was performed 3-5 more times and the supernatants were combined for each 
sample. The combined supernatant was filtered prior to HPLC analysis. Isoflavone analysis of 
prepared diets is presented in Table 4.2 
Serum Isoflavone Analysis. Serum isoflavones were analyzed by the National Center for 
Toxicological Research in Jefferson, AR using HPLC-UV. The limits of detection of genistein, 
daidzein, and equol were 0.004, 0.002, and 0.03 µM respectively.  
Histopathology. Formalin-fixed, paraffin-embedded prostate sections were stained with 
hematoxylin and eosin (H&E) and blindly evaluated by a pathologist using an established and 
published grading scheme
21
. Each lobe of the prostate was evaluated for the most severe lesion 
and the most common lesion in each lobe. Additionally, sections of liver and lungs from mice 
with gross tumors and visible lymph node metastases were evaluated for the presence of micro-
metastases. Results were compared using Fisher’s exact test between treatment groups and the 
control.   
Immunohistochemistry. Immunohistochemistry for proliferating cell nuclear antigen 
(PCNA) and cleaved caspase-3 (CC3) were performed on paraffin-embedded (4 µm) fixed 
sections of the dorso-lateral prostate lobe according to a previously published protocols
22,23
. 
Briefly, slides were placed in a decloaking chamber and treated in a citrate buffer (pH 6.0) for 30 
seconds at 125 ºC and 10 seconds at 90 ºC for antigen retrieval. In a BioGenex i6000 Automated 
Staining System (BioGenex, San Ramon, CA), endogenous peroxide was quenched with a 3% 
H2O2 solution for 15 minutes, slides were blocked with Power Block
TM
 (BioGenex) for 10 
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minutes, avidin blocked for 15 minutes, and then incubated with rabbit ant-proliferating cell 
nuclear antigen (PCNA) antibody (Abcam, Cambridge, MA) or rabbit anti-cleaved caspase-3 
(Cell Signaling, Danvers, MA) for 30 minutes and visualized using a SuperSensitive
TM
 Link-
Label IHC Detection System (BioGenex). Slides were stained with DAB and counterstained with 
hematoxylin. Mouse small intestinal tissue was used as the positive control for PCNA and mouse 
thymus tissue was used as the positive control for cleaved caspase-3. Negative controls were 
generated by omitting the primary antibody. Stained slides were scanned with a NanoZoomer 
2.0-HT digital slide scanner (Hamamatsu, Bridgewater, NJ) with Olympus Uplansapo 20X 
objective at 40X digital zoom, resulting in 0.23 µm resolution. Images were captured with NDP 
view software (Hamamatsu). One image from the dorso-lateral lobe was blindly quantified and 
the proliferative index (PI) percentage (PCNA positive-stained nuclei/ total nuclei counted x 
100) and apoptotic index (AI) percentage (number of activated caspase-3 cells/ total nuclei 
counted x 100) calculated. These indices were established by counting at least 1000 randomly 
selected cells from each image. 
Serum Testosterone. Serum testosterone was measured in TRAMP mice fed control 
(n=10), soy germ (n=10), daidzein (n=10), and equol (n=10) diets. Serum testosterone was 
extracted from 150 µL of serum using di-ethyl ether. After the ether evaporated, a hexane and 
methanol extraction was used to extract the testosterone from other serum lipids for analyses. 
Serum testosterone was evaluated using Coat-A-Count total testosterone radioimmunoassay 
(Siemens TKTT2, Los Angeles, CA). 
Serum Cytokines. Serum cytokines (IL-6, TNF-α, IL-1β, IL-10, IL-17A, and IFN-γ) 
were quantified using the Bio-Plex Pro Mouse Cytokine Th17 panel (Bio-Rad, Hercules, CA). 50 
µl of serum was mixed with multi-colored magnetic beads contained in a single well. 
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Biotinylated detection antibodies were added to quantify analytes and samples were run on the 
Bioplex Cytometric Bead Analyzer in duplicates (Bio-Rad, Hercules, CA). Differences between 
groups were analyzed using 2-tailed ANOVA followed by post-hoc Dunnetts test and specific 
contrast statements. 
Global DNA Methylation. DNA and RNA were simultaneously extracted from dorso-
lateral prostates using the Qiagen All-Prep Mini kit (Qiagen, Valencia, CA). The MethylFlash 
Quantification Colorimetric kit (Epigentek, Farmingdale, NY) was used to quantify relative and 
absolute amounts of 5-methyl-cytosine according to the manufacturer’s protocol.  
RESULTS 
Weight Gain and Feed Intake. Body weight and food intake were measured weekly and 
recorded. All diets were readily consumed and food intake was not significantly different 
between groups (Table 4.3). Average food intake was similar to other studies of TRAMP mice 
consuming pelleted diets
24,25
. Body weights were not significantly different between groups. 
Organ weights of the urogenital tract, liver, lungs, testes, gonadal adipose, spleen, ventral 
prostate, anterior prostate, and dorso-lateral prostate were not different between groups (data not 
shown).  
Serum Isoflavones. Genistein, daidzein, and equol were below the limit of detection in 
the AIN-93G control-fed mice. Genistein was only detected in mice consuming soy germ. 
Daidzein was only detected in the serum of mice fed soy germ or the daidzein diet and was 
significantly different between the two groups (p=0.048) (Table 4.4). Equol was detected in all 
the mouse serums from experimental diet groups except for the control diet and was not 
statistically different between groups. Differences in serum isoflavones between diets were 
analyzed using ANOVA and the Tukey-Kramer studentized range test (α=0.05).  
103 
 
Histopathology. There were no differences in overall combined cancer incidence 
between diet groups (Figure 4.1). Mice fed the control, soy germ, daidzein, and equol diets had a 
24%, 31%, 20%, and 28% incidence of cancer overall respectively. There was also no difference 
in cancer incidence by diet between anterior, ventral, or dorso-lateral lobes individually (data not 
shown). Furthermore, we were not able to detect any differences between pathology scores 
between diet groups (Table 4.5).  
Immunohistochemistry. There was no statistical difference between AI (Figure 4.2) or 
PI (Figure 4.3) between diet groups in prostates with HGP. There was also no difference in AI 
between diets in tumors (Figure B.8, Appendix B).    
Serum Testosterone. There were no statistical differences in serum testosterone levels 
between groups (Figure B.1 and B.2, Appendix B). Furthermore, we examined serum 
testosterone levels in wild-type non-transgenic mice (n=5/diet) to determine the impact of our 
diets on serum testosterone in a non-cancer model. There were no differences between groups, 
though the daidzein group was numerically lower than the other diet groups (Figure B.3 and B.4, 
Appendix B).  
Serum Cytokines. Serum levels of IL-1β were significantly lower in mice with tumors 
fed daidzein and equol when compared to mice with tumors fed the control and soy germ diets 
(p<0.001) (Figure 4.4). Across all diets, there was no difference in IL-1β levels in high-grade 
PIN (HGP). Mice with tumors had significantly higher levels of serum IL-6 than mice with HGP 
(p=0.004), but there were no differences between dietary treatments (Figure 4.5). Mice with 
tumors fed soy germ had significantly increased levels of IL-10 compared to mice with tumors 
fed daidzein (p=0.04) or equol (p=0.02) (Figure 4.6). Mice with tumors fed the control diet were 
not statistically different than mice fed daidzein or equol diets. With TNF-α, mice with tumors 
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fed soy germ and control had significantly higher TNF-α than mice fed daidzein (p=0.02) and 
equol (p=0.04) (Figure 4.7). Lastly, IFN-γ levels were significantly higher levels in mice with 
tumors fed daidzein (p=0.03) and equol (p=0.02) (Figure 4.8) compared to the control and soy 
germ diets. There were no differences in IL-17 levels between diets in either tumors or HGP 
(B.5, Appendix B).  
Global DNA Methylation. Global DNA methylation was measured in TRAMP dorso-
lateral prostates with confirmed HGP lesions (n=10/diet group). There was no difference in the 
percentage of 5-methyl cytosine relative to the reference standard between any of the four diet 
groups (Figure B.6, Appendix B). There was also no difference in the absolute quantification of 
5-methyl cytosine between the four diets (Figure B.7, Appendix B).  
DISCUSSION 
Due to previous findings in our laboratory
1
, we hypothesized that diets incorporating 2% 
soy germ, daidzein, or equol would equally reduce the incidence of PCa in TRAMP mice 
compared to the control diet. We further hypothesized that the mechanism would be due to the 
isoflavone metabolite, equol. Contrary to our hypothesis, we did not detect any dietary 
differences in cancer incidence. To our surprise, mice in the control group had a 24% incidence 
of cancer whereas in a previous study in our lab, mice in the control group only had a 100% 
incidence of cancer at the same 18 week time point
1
. Despite using the same animal model, 
rodent colony, animal facility, sacrifice age, lot of soy germ, and animal procedures, we were not 
able to repeat the previous findings
1
. Similar levels of isoflavones were detected in the serum and 
diets from both studies. The only difference, aside from specific diets used, was the physical 
format that the diet was provided to the rodents. Zuniga et al. fed rodents a powdered version of 
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the AIN-93G-based diets, while the current study provided the similarly-formulated diets in 
pelleted form
1
.  
The diet’s physical form resulted in drastically different food intakes between the studies. 
Zuniga et al. reported that mice consumed 5.7 grams/day while in the current study only 2.3 
grams/day were consumed
1
. It should be noted that measurement of powdered food intake is less 
precise than with pelleted food intake, as powdered food tends to be distributed in bedding and in 
the cage, so at best, we can only get an estimate of powdered food intake in these studies. 
Pelleted food intake in the current study was consistent with other studies of TRAMP mice 
consuming pelleted diets
24,25
. The differences in food intake resulted in significantly different 
body weights between the two studies (Figure 4.9). Mice fed pelleted diets in the current study, 
were significantly lighter than mice fed powdered diets in the previous study as early as 8 weeks 
of age (p<0.001) and continuing until animals were sacrificed at 18 weeks of age (Figure 4.9) 
(p<0.001).   
The associations between diet format and obesity has been examined extensively in 
rodent models
26–28
. Ford et al. described the association between food consumption and diet 
hardness in mice, and observed that increasing the hardness of food, negatively impacted growth 
and food intake
29
. Additionally, rats fed soft pellets developed obesity faster than their 
counterparts fed hard pellets
30
. Desmarchelier et al. examined the impact of feeding a control, 
high-fat, and Western diet to mice in either pelleted or powdered form
26
. The results of that study 
indicated that regardless of diet composition, all mice fed powdered diets developed similar 
weight gain
26
. This suggests that the texture of the food, rather than the nutrient composition, 
promoted hyperphagia and obesity
26
. Furthermore, in another study, long-term ingestion of 
powdered food induced hyperglycemia and systemic illness, increased adrenal gland activity, 
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and increased blood pressure in mice
27
. This could be a result of easier access to powdered foods 
(bowls of food in the cage vs. food provided above the cage in a rack), ingestion of powdered 
food from fur while cleaning, and/or faster rates of absorption of powdered food
27
. Together 
these findings suggest that the dietary format of food impacts the growth, development, and 
systemic health of healthy rodents. A diet in powdered format that contributes to excessive 
weight gain and systemic illness may promote carcinogenesis in a transgenic mouse model of 
PCa while pelleted diets might delay the onset of carcinogenesis. 
It has been previously shown that TRAMP mice fed a high-fat Western diet have 
accelerated tumor growth and tumor burden compared to the control-fed mice
31
. Alternatively, 
caloric restriction has been shown to reduce PCa incidence and progression in TRAMP mice. A 
20% dietary restriction beginning at 7 weeks of age resulted in significant reductions in PCa 
incidence at 11 and 20 weeks of age in TRAMP mice
32
. Additionally, TRAMP mice who were 
intermittently or chronically calorically restricted had a decreased incidence of PCa
24
. While in 
the current study, the mice were not calorically restricted and were allowed access to their food 
ad libitum, they consumed nearly 50% fewer grams of food/day than mice fed powdered food 
and weighed significantly less than mice fed powdered food
1
. This reduction in food intake 
might account for the reduction in cancer incidence observed. 
However, changes in caloric intake and energy balance and expenditure also alters cancer 
incidence in TRAMP mice. While caloric restriction alone has been shown to reduce cancer 
incidence in the TRAMP model, changes in energy balance and excess caloric retention 
contribute to cancer progression. Mice housed at 22 ºC expend more energy and have lower body 
mass than mice housed closer to their thermoneutral zone (30-35 ºC)
33
. Interestingly, when mice 
are housed a 22 ºC, they consume 30% more calories, but have less body mass than mice housed 
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at 27 ºC
33
.  This suggests that mice consume more food to compensate for thermoregulatory 
demands, but that energy balance plays a role beyond food intake. The use of pelleted diets in the 
current study and the temperature mice were housed at (22 ºC) combined to produce an 
environment where mice had to expend energy to consume food and expend energy to maintain 
thermoregulation, ultimately keeping their body weight lower. These results suggest that pelleted 
diets fed ad libitum resulted in decreased body weight and decreased cancer incidence compared 
to mice fed powdered diets ad libitum
1
. The decrease in body weight was likely a contributing 
factor to the decrease in expected cancer incidence in all dietary treatment groups.  
Evidence exists that inflammation plays a critical role in the development and 
progression of PCa
34
. We measured serum levels of pro-inflammatory and anti-inflammatory 
cytokines in TRAMP mice displaying gross primary prostate tumors and compared them to mice 
with histopathologically confirmed high-grade PIN (HGP) prostates across all four diets. While 
cancer incidences were not different between our diets, serum levels of cytokines varied 
significantly by diet when we compared preneoplastic prostates to mice with developed prostate 
tumors. Interestingly, we observed a pattern in several serum cytokines measured that the 
daidzein and equol diets had significantly different serum cytokine levels than the soy germ and 
control diets.  In mice with tumors, the daidzein and equol-fed groups had significantly lower 
levels of circulating IL-1β than the control and soy germ groups (Figure 4.2). IL-1β has been 
shown in C4-2 PCa cells to drive PCa progression by inhibiting AR expression and inducing 
p62
35
. Additionally, tumor IL-1β levels remained independent prognostic factors in human 
prostatectomy samples, suggesting that IL-1β might be indicative of clinical outcomes36. The 
significant decrease in IL-1β levels in mice with tumors by daidzein and equol diets may suggest 
that these diets may have anti-inflammatory properties beneficial in delaying or reducing PCa 
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progression to advanced or castration-resistant PCa. In contrast, IL-1β has also been shown in 
LNCaP prostate cancer cells to inhibit proliferation and reduce PSA production through NF-κB 
activation
37
. Consistent with our histolopathological data and proliferation results, there was no 
difference in IL-1β serum levels between diets in mice with prenoplastic HGP prostates. 
Therefore, it appears that IL-1β may have dual action in PCa in that it confers protection in 
precancerous stages of PCa and may contribute to the progression of advanced PCa.  
Additionally, IFN-γ and TNF-α were also significantly reduced by the daidzein and equol 
diets in serum of mice with tumors than in the control and soy germ groups (Figure 4.8, Figure 
4.7). TNF-α is a major pro-inflammatory cytokine secreted in the tumor micro-environment that 
can activate PCa progression signaling pathways
36
. Prostatic expression of TNF-α from human 
prostatectomy samples has also been suggested to indicate clinical outcomes in PCa
36
.  The 
impact of consumption of soy foods on TNF-α levels have yielded mixed results in the 
literature
38,39
.  
IFN-γ is a type II interferon produced by CD4+ lymphocytes and natural killer (NK) 
cells
40
. In a mouse model of PCa, IFN-γ treatment led to a 3-fold increase in apoptosis in the 
primary prostate tumor
40
. Moreover, IFN-γ has been shown to promote anti-tumor responses in 
several cancers
41
. In this study, we observed a significant decrease in IFN-γ in serum from mice 
with tumors fed daidzein and equol (Figure 4.8). While there has been no correlation between 
levels of IFN-γ and cancer severity, the decreased IFN-γ levels in the daidzein and equol-fed 
groups warrant further investigation as increased IFN-γ levels are associated with protection 
against PCa.  
Daidzein and equol also significantly reduced serum levels of IL-10 in mice with tumors 
compared to the soy germ diet (Figure 4.6).  IL-10 is generally known to be an anti-
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inflammatory cytokine, but studies in human prostate tissue have shown it to be increased in 
advanced PCa
42
. This further indicates that daidzein and equol may potentially mediate the 
tumoral inflammatory environment.  
Serum levels of IL-6 were significantly increased across all diets in mice with tumors 
than in mice with HGP (Figure 4.5). IL-6 has been shown to activate AR and enhance PCa 
growth
43
.  While there was no effect of diet on serum IL-6, the increase in IL-6 in mice with 
prostate tumors is consistent with the literature. An IL-6 super-antagonist has been shown to 
inhibit the growth of PC-3 xenografted cells in mice
43
. This suggests that therapies targeted to 
decrease levels of IL-6 may be beneficial in the future against PCa.   
Interestingly, we did not observe any reductions in serum levels of cytokines in mice fed 
the soy germ diet, but we did observe differences by the daidzein (matched for daidzein 
equivalents in the 2% soy germ diet) and equol diets. While the primary isoflavone in soy germ 
was daidzein, the interactions between daidzein, glycitein, and genistein from the whole soy 
germ along with saponins, lignans, and vitamin E in the soy germ food matrix may have 
impacted soy germ’s efficacy on modulating serum cytokines. Together, the main outcome of 
cancer incidence was not different between diets; however, daidzein and equol diets reduced 
levels of pro-inflammatory cytokines in the serum of mice with tumors suggesting that these two 
diets may be beneficial in reducing systemic inflammation in advanced PCa.  
In this study, cancer incidence was remarkably lower in the TRAMP model than previous 
studies in our lab
1,44
. The reduction in cancer incidence may be explained by a change in dietary 
format from powdered to pelleted diets. The combination of feeding pelleted diets and housing 
mice individually below their thermonuetral zone may have shifted energy balance in TRAMP 
mice to only eat enough for maintenance and growth. Future studies utilizing pelleted diets might 
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detect differences between dietary treatments by prolonging the sacrifice age further than 18 
weeks to allow for cancer development or switching back to powdered diets. Despite null results 
regarding cancer incidence, we observed a significant effect of daidzein and equol on serum 
cytokines in mice with prostate tumors. This may suggest that daidzein and equol diets, but not a 
whole soy germ diet, may have anti-inflammatory properties in advanced stage PCa. Future 
studies in TRAMP mice should examine serum cytokine levels as well as prostatic and tumoral 
mRNA expression of cytokines to confirm these findings.  
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FIGURES AND TABLES 
Table 4.1. Composition of Experimental Diets 
 g/100g total diet 
 
Control 2% Soy Germ
 a 
Daidzein 
b 
Equol 
c 
Cornstarch 39.7 39.8 39.7 39.7 
Casein 20 19 20 20 
Maltodextrin 13.2 13.2 13.2 13.2 
Sucrose 10 10 10 10 
Fiber 
d 
5 4.3 5 5 
Mineral Mix 
e 
3.5 3.5 3.5 3.5 
Vitamin Mix 
f 
1 1 1 1 
L-Cystine 0.3 0.3 0.3 0.3 
Choline Bitrate 0.25 0.25 0.25 0.25 
Corn Oil 7 6.5 7 7 
TBHQ, antioxidant 0.0014 0.0014 0.0014 0.0014 
Soy Germ 
g 
0 2 0 0 
Daidzein 0 0 0.0092 0 
Equol 0 0 0 0.0088 
a 
2% Soy Germ diet contains 71 ppm daidzein equivalents, 68 ppm glycitein equivalents, and 35 
ppm genistein equivalents 
b
 Daidzein diet contains 92 ppm daidzein equivalents 
c
 Equol diet contains 88 ppm equol equivalents 
d 
Non-nutritive cellulose 
e
 AIN-93G-MX formation 
f
 AIN-93G-VX formation 
g
 Frutarom SoyLife® Complex Micro  
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Table 4.2. Isoflavone Analyses of the Prepared Diet (ppm) 
Diet 
AIN-93G + 2% Soy 
Germ (ppm) 
AIN-93G + 92 
ppm Daidzein 
(ppm) 
AIN-93G + 88 
ppm Equol 
(ppm) 
Genistein 35 0 0 
Daidzein 71 90 0 
Glycitein 68 0 0 
Equol 0 0 80 
Values are the mean of n=5. 
 
Table 4.3. TRAMP Body Weights and Food Intake 
 
AIN-93G 
Control 
AIN-93G + 2% 
Soy Germ 
AIN-93G + 92 
ppm Daidzein 
AIN-93G + 
88 ppm 
Equol 
Beginning Body 
Weight (g) 
20.2 ± 
3.7 
19.4 ± 3.6 20.3 ± 3.8 20.6 ± 3.8 
Ending Body 
Weight (g) 
27.3 ± 5 27 ± 5 27.7 ± 5 28 ± 5 
Average Food 
Intake (g/day) 
2.3 ± 0.4 2.3 ± 0.4 2.3 ± 0.4 2.2 ± 0.4 
n 30 29 30 30 
Values are the mean ± SEM.  
 
 
Table 4.4. TRAMP Serum Isoflavone Analyses 
       Isoflavone                                                Serum (μM) 
Diet Control 2% Soy Germ Daidzein Equol 
Genistein ND
 
0.11 ± 0.05 ND
 
ND 
Daidzein ND 0.44 ± 0.27 
a
 0.17 ± 0.18 
b 
ND 
Equol ND 2.67 ± 1.92 1.44 ± 0.46 3.37 ± 2.12 
Values are Mean ± SEM 
ND = Not detected in the serum 
Superscript letters in the same row indicate a significant difference between groups (p=0.048). 
n=7 per group 
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Figure 4.1. Overall Prostate Cancer Incidence in TRAMP mice 
 
Different colored bars represent the distribution of cancer severity among diets. 
n=29-30/diet group 
Table 4.5. TRAMP Histopathology Results as a Percentage of Total Prostatic Lesions by Diet 
   
PIN 
 
Adenocarcinoma Prostate 
Cancer 
(WD-PD) TRAMP 
         
Diet n NP LGP MGP HGP PLL WD MD PD 
 AIN-93G 
Control 
29 7% 0% 21% 41% 7% 3% 10% 
10
% 
24% 
AIN-93G + 2% 
Soy Germ 
29 0% 3% 3% 55% 7% 3% 0% 
28
% 
31% 
AIN-93G + 82 
ppm Daidzein 
29 3% 7% 3% 66% 0% 3% 7% 
10
% 
20% 
AIN-93G + 88 
ppm Equol 
29 0% 0% 3% 59% 10% 3% 17% 7% 28% 
NP = Normal Prostate, LG = low grade PIN, MG = moderate grade PIN, HG = high-grade PIN, 
PLL = phyllode-like lesions, WD = well differentiated, MD = moderately differentiated, PD = 
poorly differentiated.  
Results are the incidence of each stage of pathology and overall incidence (sum of WD-PD) 
within dietary groups. 
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Figure 4.2. TRAMP Prostatic Apoptotic Index  
 
Values are means ± SEM.  
n=5/diet groups 
 
Figure 4.3. TRAMP Proliferation Index 
 
Values are means ± SEM.  
n=5/diet groups 
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Figure 4.4. TRAMP Serum IL-1β 
 
Values are means ± SEM.  
n=6-7/diet groups 
Different capital letters indicate significant differences between diet groups in tumors (p<0.05). 
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Figure 4.5. TRAMP Serum IL-6 
 
Values are means ± SEM.  
n=6-7/diet groups 
Different capital letters indicate significant differences between tumor and HGP (p<0.05).  
Figure 4.6. TRAMP Serum IL-10 
 
Values are means ± SEM.  
n=6-7/diet group 
Different capital letters indicate significant differences between diet groups within tumors 
(p<0.05).  
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Figure 4.7. TRAMP Serum TNF-α 
 
Values are means ± SEM.  
n=6-7/diet groups 
Different capital letters indicate significant differences between diet groups within tumors 
(p<0.05).  
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Figure 4.8. TRAMP Serum IFN-γ 
 
Values are means ± SEM.  
n=6-7/diet groups 
Different capital letters indicate significant differences between diet groups within tumors 
(p<0.05).  
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Figure 4.9. TRAMP Body Weight Comparison between Zuniga et al. and Conlon et al.  
 
Values represent the mean body weight across all diets at each week of age.  
* Represents a significant difference (α<0.05) between Zuniga et al. and the current study, 
Conlon et al. at specific time points. 
Both studies n=29-31 weighed at each time point.  
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CHAPTER 5 
Summary and Future Directions 
PCa is the most commonly diagnosed male cancer in the United States. There is a 
growing body of evidence that suggests a diet rich in fruits and vegetables, specifically tomato 
and soy, may protect against PCa. While many studies have demonstrated the effectiveness of 
the individual components of tomatoes and soy, carotenoids and isoflavones, in cancer 
development and progression, people primarily consume these bioactives from whole foods. 
Therefore, not only should researchers study the effects of dietary bioactives, they should also 
consider the matrix of the whole food and the co-consumption of other nutrients and food 
components within a meal.  
 In Chapter 2, we aimed to determine if the saturation and chain length of dietary fat co-
consumed with a 10% TP diet would impact the bioavailability of tomato carotenoids and affect 
their tissue distribution in the Mongolian Gerbil. In this study, we observed differential tissue 
accumulation patterns of dietary carotenoids. The specific carotenoid profiles in each tissue may 
reflect differences in metabolism of carotenoids in tissues. Furthermore, we observed that the 
coconut oil diet increased carotenoid bioaccumulation in all tissues measured except for the 
spleen and skin compared to safflower oil. This increased bioaccumulation of tomato carotenoids 
may have been the result of increased carotenoid solubility in the intestinal lumen, enhanced 
portal absorption with medium-chain triglycerides from coconut oil, and/or a reduction in hepatic 
cholesterol uptake induced by coconut oil. Nonetheless, this finding is significant because it 
emphasizes that the type of dietary fat co-consumed with carotenoid-containing foods is 
important in the tissue distribution of carotenoids. While coconut oil consumption resulted in the 
greatest tissue accumulation of tomato carotenoids, it also significantly increased serum 
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cholesterol in this study. Therefore, a decision to incorporate coconut oil into diets to increase 
carotenoid bioaccumulation should be balanced with the negative consequences of saturated fat 
on overall health. Future studies should focus on identifying the mechanisms for differential 
carotenoid accumulation between tissues and investigate whether shifts in tissue fatty acid 
profiles enhanced carotenoid accumulation.  
 In Chapter 3, we evaluated if a 10% TP intervention could reduce PCa incidence in the 
TRAMP model. Previous evidence from epidemiological and animal studies suggested that a diet 
rich in tomato products may protect against PCa. However, previous animal studies model 
lifelong dietary consumption of TP or lycopene. Because the use of complementary and 
alternative medicine is prevalent among cancer patients and may not be initiated until cancer 
diagnosis, we evaluated if a 10% TP diet could decrease the risk for PCa when fed post-puberty 
when preneoplastic lesions were present. All TRAMP mice were fed the control diet (AIN-93G) 
from 3 weeks of age to 8 weeks of age when they were randomized to either continue consuming 
the control diet or consume the experimental diet (AIN-93G + 10% TP) until 12, 16, or 20 weeks 
of age. We found no change in overall cancer incidence by 10% TP diet at 12, 16, or 20 weeks of 
age. We did, however, observe a significant increase in HGP and a significant decrease in PD 
lesions by TP diet only at 16 weeks of age, although total cancer incidence at 16 weeks of age 
was not significantly different. This modest change may suggest that a 10% TP diet intervention 
delayed the progression of precancerous lesions to cancerous lesions at 16 weeks of age.  
The lack of a dramatic effect in cancer incidence by TP may have been the result of two 
variables in our study: 1) the tomato carotenoid profile of the diet and 2) the timing of our 
intervention. The carotenoid content of the TP fed contained 30-fold less lycopene than our 
previous TRAMP study which might suggest there is a threshold of lycopene necessary to reduce 
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carcinogenesis in this model
1,2
. However, tissue lycopene concentrations at 16 and 20 weeks of 
age were similar to a previous study using TRAMP mice in our lab, suggesting that tissue 
accumulation of carotenoids may reach a saturation point in tissues, including the prostate.  
The second variable in our study was the timing of our intervention. The timing of our 
intervention may have been too late in carcinogenesis in TRAMP mice. Prior research by our 
group has shown that the TRAMP genotype altered several prostatic genes involved in cell-cycle 
and cell growth by 10 weeks of age
3
. Furthermore, 6 weeks of a 10% TP diet altered expression 
of genes involved in androgen signaling and synthesis in the prostate of TRAMP mice by 10 
weeks of age
3
. The dietary intervention in the current study was initiated at 8 weeks of age when 
mice had confirmed low- and moderate-grade PIN lesions in the prostate (confirmed by 
sacrificing a small sub-cohort of mice at 8 weeks of age) and after the onset of puberty. 
Carcinogenesis in the TRAMP model begins in response to androgens at puberty, or around 6 
weeks of age. The response of the rat probasin promoter to androgens at puberty results in the 
expression of the Simian virus 40 large T antigen in the prostate epithelium. This results in the 
suppression of tumor suppressors, p53 and Rb, and uncontrolled proliferation and mutations in 
the prostate. Perhaps beginning a TP diet intervention after the onset of puberty during a time 
when PIN lesions were developing was too late to substantially impact carcinogenesis in this 
model. Equally plausible, is that the combination of a low-lycopene-containing TP and a late 
intervention time contributed to our results. While it appears that lycopene reaches saturation in 
some tissues with long-term feeding, TP diets may only be effective in this model when they 
contain enough lycopene to modulate androgen signaling and metabolism early in 
carcinogenesis, a threshold still to be determined. As reviewed Chapter 3, animal studies 
providing 28 ppm lycopene
4
 and 12.3 ppm lycopene (the current study), were ineffective in 
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reducing the risk of PCa in TRAMP mice. However when TP contained more lycopene (132-286 
ppm), they were effective at reducing PCa incidence
1,5
. Nonetheless, this study supports the 
importance of lifelong consumption of tomato products for PCa prevention. Future studies 
should aim to identify if there is a critical window of lycopene exposure necessary to alter PCa in 
this model and if this impacts its translation to human PCa outcomes.  
 In Chapter 4, we aimed to further elucidate the mechanism by which a 2% soy germ diet 
reduced the incidence of PCa in the TRAMP model
1
. We hypothesized that the effect of soy 
germ was primarily due to the microbial metabolite of daidzein, equol. TRAMP mice were 
randomized at weaning to consume one of four pelleted study diets: AIN-93G, AIN-93G + 2% 
soy germ, AIN-93G + 92 ppm daidzein, or AIN-93G + 88 ppm equol until 18 weeks of age. 
Diets were pelleted to better assess food intake. To our surprise, only a fraction of the mice in 
this study had cancerous lesions, and the majority of mice had pre-neoplastic lesions at sacrifice. 
This effect was surprising as we designed this study to further investigate the results of a 
previous study in our lab
1
. The only difference between studies, aside from treatment groups, 
was the physical format we provided the study diets to the mice.  
As a result, providing study diets in pelleted form significantly reduced food intake and 
impacted the outcomes of the study. Other labs have shown that mice who consumed powdered 
diets gained more body weight, had increased blood pressure, and displayed other systemic 
effects than mice fed pelleted diets
6,7
. When we compared the current study’s body weight values 
with mice from the Zuniga et al. study, our mice had significantly reduced body weights. We 
conclude that mice in the current study failed to develop cancer to the extent expected as mice on 
the same experimental protocol (aside from dietary treatment groups and diet form), because 
they gained less body weight as a result of altered energy expenditure and a reduction in food 
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intake. Future studies should take dietary format into consideration during the design of the study 
and if pelleted diets are to be utilized, the sacrifice age should be adjusted to ensure expected 
cancer incidence rates in control mice.  
 Additionally, we investigated the effects of soy germ, daidzein, and equol on serum 
cytokines in a sub-set of TRAMP mice with HGP and tumors. Interestingly, we observed that 
daidzein and equol-fed mice with tumors had significant reductions in IL-1β, IL-10, and TNF-α. 
These effects suggest that daidzein and equol diets reduced systemic inflammation in mice with 
advanced PCa. In contrast, daidzein and equol diets also significantly reduced serum levels of 
IFN-γ. Increased levels of IFN-γ has been thought to be protective in PCa prevention, so the 
reduction of this cytokine by the daidzein and equol diets was surprising
8,9
. While this study only 
investigated serum levels of cytokines, future studies should aim to determine if prostatic or 
tumoral mRNA expression of these cytokines are affected by diet.  
 In conclusion, people consume foods as parts of meals. While it’s important to determine 
mechanisms of specific bioactives from whole foods, there is a need to consider the effects of 
factors during a meal which may limit or enhance the bioavailability of bioactives. Much 
remains to be known about how diet can impact PCa development and progression over the 
lifespan and its possible mechanisms for protection. But the long latency period between PCa 
diagnosis and PCa treatment provides an ideal window for dietary modifications.  
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APPENDIX A 
Supplemental Tables and Figures 
Figure A.1. TRAMP Serum Testosterone by Age and Diet 
 
Values represent the mean ± SEM 
n=20 per diet per age 
# Indicates a significant difference (p<0.05) from the control diet within each age.  
 
Figure A.2. TRAMP Prostatic mRNA Expression of Androgen Receptor by Age and Diet 
 
Values represent the mean ± SEM.  
# Indicates a significant difference between ages (p < 0.05).   
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Figure A.3. TRAMP Prostatic Androgen Receptor Expression by Pathology 
 
Values represent the mean ± SEM.  
# Indicates a significant difference between pathologies (p < 0.05).  
Figure A.4. TRAMP Prostatic mRNA Expression of 5α-Reductase I and II by Diet and 
Pathology 
 
Values represent the mean ± SEM.  
# Indicates a significant difference in 5α-Reductase II expression between pathologies  (p < 
0.05).  
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Figure A.5. TRAMP Prostatic mRNA CYP17A1 Expression by Diet and Pathology 
 
Values represent the mean ± SEM.  
# Indicates a significant difference between pathologies (p < 0.05).  
Figure A.6. TRAMP Prostatic mRNA Expression of HSD17β2 and HSD17β3 by Diet and 
Pathology 
 
Values represent the mean ± SEM.  
# Indicates a significant difference between pathologies in HSD17β3 levels (p < 0.05).  
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Figure A.7. TRAMP Prostatic mRNA Expression of msmb by Diet and Pathology 
 
Values represent the mean ± SEM.  
# Indicates a significant difference between pathologies (p < 0.05).  
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Figure A.8. 3-D Prostate Tumor Volume vs. Gross Tumor Mass
 
 Data points represent individual animal values 
n=10 
Figure A.9. Longitudinal 3-D Volumes of Mouse  Prostate Tumors 
 
Values represent the mean ± SEM 
Tomato (n=5), Control (n=6) 
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Figure A.10. Gross Prostate Tumor Volume vs. 3-D Tumor Volume 
 
 Data points represent individual animal values  
n=7 
Figure A.11. Longitudinal 3-D Volumes of Mouse Prostates without Tumors 
 
Values represent the mean ± SEM 
Tomato (n=9), Control (n=8) 
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APPENDIX B 
Supplemental Tables and Figures 
 
Figure B.1. TRAMP Serum Testosterone       Figure B.2. TRAMP Serum Testosterone 
 
Values represent mean ± SEM.    Values are individual data points. 
 
n=10/diet group 
 
Figure B.3. Wild-type Serum Testosterone       Figure B.4. Wild-type Serum Testosterone 
 
Values represent mean ± SEM.    Values are individual data points. 
n=10/diet group 
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Figure B.5. TRAMP Serum IL-17 
 
Values are means ± SEM.  
n=6-7/ diet group 
Different letters indicate significant differences between diet groups with the same pathology (p 
< 0.05). 
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Figure B.6. Relative Prostatic Global DNA Methylation 
 
Values represent mean ± SEM 
n=10/diet group 
Figure B.7. Absolute Prostatic Global DNA Methylation 
 
Values represent mean ± SEM 
n=10/diet group 
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Figure B.8. Tumoral Apoptotic Index 
 
Values represent mean ± SEM 
n=5/diet group 
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